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A B S T R A C T
Background
Currently, with stroke burden increasing, there is a need to explore therapeutic options that ameliorate the acute insult. There is
substantial evidence of a neuroprotective effect of marine-derived n-3 polyunsaturated fatty acids (PUFAs) in experimental stroke,
leading to a better functional outcome.
Objectives
To assess the effects of administration of marine-derived n-3 PUFAs on functional outcomes and dependence in people with stroke.
Our secondary outcomes were vascular-related death, recurrent events, incidence of other type of stroke, adverse events, quality of life,
and mood.
Search methods
We searched the Cochrane Stroke Group trials register (6 August 2018), the Cochrane Central Register of Controlled Trials (CENTRAL;
Issue 1, January 2019), MEDLINE Ovid (from 1948 to 6 August 2018), Embase Ovid (from 1980 to 6 August 2018), CINAHL
EBSCO (Cumulative Index to Nursing and Allied Health Literature; from 1982 to 6 August 2018), Science Citation Index Expanded
Web of Science (SCI-EXPANDED), Conference Proceedings Citation Index-Science - Web of Science (CPCI-S), and BIOSIS
Citation Index. We also searched ongoing trial registers, reference lists, relevant systematic reviews, and used the Science Citation Index
Reference Search.
Selection criteria
We included randomised controlled trials (RCTs) comparing marine-derived n-3 PUFAs to placebo or open control (no placebo) in
people with a history of stroke or transient ischaemic attack (TIA), or both.
Data collection and analysis
At least two review authors independently selected trials for inclusion, extracted data, assessed risk of bias, and used the GRADE
approach to assess the quality of the body of evidence. We contacted study authors for clarification and additional information on
stroke/TIA participants. We conducted random-effects meta-analysis or narrative synthesis, as appropriate. The primary outcome was
efficacy (functional outcome) assessed using a validated scale e.g. Glasgow Outcome Scale Extended (GOSE) dichotomised into poor
or good clinical outcome, Barthel Index (higher score is better; scale from 0 to 100) or Rivermead Mobility Index (higher score is better;
scale from 0 to 15).
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Main results
We included 29 RCTs; nine of them provided outcome data (3339 participants). Only one study included participants in the acute
phase of stroke (haemorrhagic). Doses of marine-derived n-3 PUFAs ranged from 400 mg/day to 3300 mg/day. Risk of bias was
generally low or unclear in most trials, with a higher risk of bias in smaller studies. We assessed results separately for short (up to three
months) and longer (more than three months) follow-up studies.
Short follow-up (up to three months)
Functional outcome was reported in only one pilot study as poor clinical outcome assessed with GOSE (risk ratio (RR) 0.78, 95%
confidence interval (CI) 0.36 to 1.68; 40 participants; very low quality evidence). Mood (assessed with GHQ-30, lower score better),
was reported by only one study and favoured control (mean difference (MD) 1.41, 95% CI 0.07 to 2.75; 102 participants; low-quality
evidence).
We found no evidence of an effect of the intervention for the remainder of the secondary outcomes: vascular-related death (two studies,
not pooled due to differences in population, RR 0.33, 95% CI 0.01 to 8.00, and RR 0.33, 95% CI 0.01 to 7.72; 142 participants;
low-quality evidence); recurrent events (RR 0.41, 95% CI 0.02 to 8.84; 18 participants; very low quality evidence); incidence of other
type of stroke (two studies, not pooled due to different type of index stroke, RR 6.11, 95% CI 0.33 to 111.71, and RR 0.63, 95% CI
0.25 to 1.58; 58 participants; very low quality evidence); and quality of life (physical component mean difference (MD) −2.31, 95%
CI −4.81 to 0.19, and mental component MD −2.16, 95% CI −5.91 to 1.59; one study; 102 participants; low-quality evidence).
Adverse events were reported by two studies (57 participants; very low quality evidence), one trial reporting extracranial haemorrhage
(RR 0.25, 95% CI 0.04 to 1.73) and the other one reporting bleeding complications (RR 0.32, 95% CI 0.01 to 7.35).
Longer follow-up (more than three months)
One small trial assessed functional outcome with both Barthel Index (MD 7.09, 95% CI −5.16 to 19.34) for activities of daily living,
and Rivermead Mobility Index (MD 1.30, 95% CI −1.31 to 3.91) for mobility (52 participants; very low quality evidence). We carried
out meta-analysis for vascular-related death (RR 1.02, 95% CI 0.78 to 1.35; five studies; 2237 participants; low-quality evidence) and
fatal recurrent events (RR 0.69, 95% CI 0.31 to 1.55; three studies; 1819 participants; low-quality evidence).
We found no evidence of an effect of the intervention for mood (MD 1.00, 95% CI −2.07 to 4.07; one study; 14 participants; low-
quality evidence). Incidence of other type of stroke and quality of life were not reported.
Adverse events (all combined) were reported by only one study (RR 0.94, 95% CI 0.56 to 1.58; 1455 participants; low-quality evidence).
Authors’ conclusions
We are very uncertain of the effect of marine-derived n-3 PUFAs therapy on functional outcomes and dependence after stroke as there
is insufficient high-quality evidence. More well-designed RCTs are needed, specifically in acute stroke, to determine the efficacy and
safety of the intervention.
Studies assessing functionality might consider starting the intervention as early as possible after the event, as well as using standardised
clinically-relevant measures for functional outcomes, such as the modified Rankin Scale. Optimal doses remain to be determined;
delivery forms (type of lipid carriers) and mode of administration (ingestion or injection) also need further consideration.
P L A I N L A N G U A G E S U M M A R Y
Marine-derived fatty acid therapy for stroke
Review question
To assess the effect of marine-derived omega-3 fatty acids for stroke after a short (up to three months) and a longer (more than three
months) follow-up.
Background
The term stroke refers to a group of diseases of blood vessels in the brain. Stroke can be caused by either bleeding or blockage in these
vessels that leads to a loss of function of brain cells. Transient ischaemic attack (TIA), also called a ’mini-stroke’, is a temporary disruption
of blood supply to the brain. Stroke is a disabling disease that usually requires prolonged specialised care and currently there are few
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treatment options for stroke patients. Omega-3 fatty acids - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - present
in oily fish have important functions in the brain. In animal research, they appear to protect the brain cells after stroke particularly if
they are administered very early. However, the effects of EPA and DHA as a treatment for stroke in humans are unclear.
Study characteristics
We identified 29 studies that included participants with stroke or TIA and we found relevant information in nine of them (3339
participants in total). Three had a short follow-up (up to three months) and six had a longer follow-up. Three studies compared marine-
derived omega-3 fatty acids to normal care and the remainder used a placebo (dummy). Not all the studies assessed all outcomes.
Key results
Effects of marine-derived omega-3 fatty acids are unclear for stroke recovery. Only two very small studies reported it, without finding
significant differences. One study found less improvement in mood with marine-derived omega-3 fatty acids but the evidence was of
low quality. The effect of marine-derived omega-3 fatty acids on vascular-related death, recurrence of stroke, adverse events, and quality
of life after having a stroke or TIA is unclear, due to the small number of studies that have assessed them.
Quality of the evidence
In the short follow-up, we considered the quality of the evidence very low for recovery, recurrence, frequency of other type of stroke
(bleeding or blockage), and adverse events, and low for vascular-related death, quality of life, and mood. For the longer follow-up, the
evidence was of very low quality for recovery from stroke, and low quality for vascular-related death, recurrence, adverse events, and
mood. Frequency of other type of stroke and quality of life were not reported in the long follow-up.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy for stroke: short follow-up (three months or less)
Patient or population: stroke and/ or TIA
Setting: hospital, outpat ient, community, or home
Intervention: marine-derived n-3 fatty acids therapy
Comparison: no marine-derived n-3 fatty acids therapy
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
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5 Sample size too small f or tool employed. Downgraded 1 level
6 Small sample size. Downgraded 1 level
























































































B A C K G R O U N D
Description of the condition
Stroke, defined as the acute onset of a persistent focal neurolog-
ical deficit related to a specific cerebrovascular location (Barret
2013), is a general term that comprises different diseases involv-
ing blood vessels supplying the brain (Caplan 2006). Strokes can
be broadly classified as haemorrhagic or ischaemic. Haemorrhagic
stroke mainly includes intracerebral haemorrhage (ICH) and sub-
arachnoid haemorrhage (SAH), which account for 5% to 15%,
and 5%, respectively, of all acute strokes (Barret 2013). Ischaemic
stroke, which can be generated by thrombosis, embolism, or sys-
temic hypoperfusion, leads to a lack of blood supply for nor-
mal functioning of the brain tissue (Caplan 2006). From around
790,000 cases of new or recurrent strokes registered each year in
the USA, up to 87% are ischaemic (Mozaffarian 2016). Transient
ischaemic attacks (TIAs) are temporary disruptions in circulation
to a part of the brain (Caplan 2006). Two regions are found within
the infarct in ischaemic stroke: the necrotic core, which is irre-
versibly injured due to rapid cell death; and the ischaemic penum-
bra, an area that surrounds the core and where neurons remain po-
tentially salvageable (Blondeau 2016; Yao 2013). The penumbra
has a life span of only a few hours and, during this period, reper-
fusion or neuroprotective therapy is needed to prevent irreversible
damage (Yao 2013).
In response to stroke, physiological and structural changes take
place in neuronal circuits surrounding the infarct in order to stim-
ulate neural repair. These include the formation of new connec-
tions in cortical areas (termed axonal sprouting, which is also influ-
enced by neurorehabilitation), neural progenitor responses (neu-
rogenesis and gliogenesis), and changes in neuronal excitability in
peri-infarct tissue (Carmichael 2016). However, reperfusion af-
ter ischaemia can, paradoxically, result in enhanced tissue injury
(Eltzschig 2011). Therefore, neuroprotectants that potentially at-
tenuate damage related to reperfusion injury are also needed. Fur-
thermore, theoretically beneficial compounds may also have ad-
verse effects during the recovery phase, considering that stability
and protection are required in the acute phase, whereas neuronal
plasticity is needed during the following stages (Carmichael 2016).
The timing of intervention is critical for optimal recovery after
stroke: alteplase is effective when administered within 4.5 hours
from stroke ictus (Hacke 2008), while clot retrieval is beneficial up
to 7.3 hours (Saver 2016), and up to 24 hours in selected patients
(Nogueira 2018). Due to public awareness campaigns, more peo-
ple are arriving in emergency departments early after the event,
but other than intravenous thrombolysis or thrombectomy, there
are no evidence-based neuroprotective agents currently available.
In contrast with other cardiovascular events, stroke tends to leave
permanent sequelae and generally requires long-term rehabilita-
tion and specialised care (Tanaka 2008). In 2016, there were more
than 80 million stroke survivors worldwide and global stroke bur-
den is increasing (Feigin 2019). For these reasons, the need to ex-
plore therapeutic options to ameliorate the acute insult remains.
Description of the intervention
High oily fish intake has been related to a reduced mortality from
coronary (Hu 2002), and ischaemic heart disease (Zhang 1999),
in both sexes. Epidemiological studies have reported mixed results
regarding stroke: while some observed an inverse relationship be-
tween fish intake and stroke incidence (Gillum 1996; Keli 1994),
and mortality (Zhang 1999), others have found no significant ef-
fect (Morris 1995; Orencia 1996). Considering the nature of ob-
servational studies, potential confounding factors - such as lifestyle
and other dietary compounds - need to be taken into account when
assessing the evidence. As oily fish is an important source of omega-
3 (n-3) polyunsaturated fatty acids (PUFAs), mainly eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) (Saravanan
2010), potential effects of fish intake on cardiovascular diseases
have been attributed to these n-3 PUFAs.
EPA and DHA are synthesised by marine algae and are concen-
trated in fish and marine oils, while terrestrial plant n-3 fatty acids
sources contain only the n-3 precursor alpha-linolenic acid (ALA)
(Bradbury 2011; Valenzuela 2009). EPA and DHA make up ap-
proximately 30% of the fatty acids present in fish oil; however, their
proportion varies according to the type of fish (Calder 2012a).
Presently, apart from seafood, these fatty acids can be found in
supplements of fish oil, fish liver oil, krill oil, and also as pharma-
ceutical grade ethyl ester formulations (Calder 2009). Availability
of n-3 PUFAs has allowed pharmacological intervention trials us-
ing highly purified fatty acids concurrently with food-based trials
(Yokoyama 2007). Current intake recommendations of marine-
derived n-3 PUFAs from different health bodies in Western coun-
tries are around 500 mg per day of combined EPA and DHA, the
equivalent of two oily-fish meals per week (Kris-Etherton 2009).
EPA comprises 20 carbon atoms and five double bonds and it is
required for production of eicosanoids (Bradbury 2011). EPA, in
its ethyl ester form, has been approved in Japan as a treatment for
hyperlipidaemia and peripheral artery disease (Yokoyama 2007).
Furthermore, it has been shown to reduce the recurrence of stroke
in a Japanese hypercholesterolaemic population (Tanaka 2008).
DHA, with the longest side chain (22 carbon atoms) and six double
bonds, is particularly concentrated in membrane phospholipids of
nervous tissues (Valenzuela 2013), and it is critical for maintaining
normal retinal and brain structure and function (Bradbury 2011).
DHA is essential for normal brain growth (McNamara 2006),
and cognitive function (Bazan 2009): supplies are required for
membrane replacement, maintaining synaptic integrity and func-
tion, gene regulation, and synthesis of neuroprotectins (Bazinet
2014). DHA also plays a critical role in neuronal survival and is a
potent modulator of brain inflammation (Bazinet 2014). DHA,
therefore, has potential roles in prevention and attenuation of is-
7Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
chaemic injury, and also in facilitating repair and neuroplasticity
after stroke (Belayev 2011).
How the intervention might work
Increasing intakes of n-3 PUFAs from fatty fish could positively
influence the prevention of stroke (Ikeya 2013). Furthermore, in
people with acute ischaemic stroke a low serum n-3/n-6 PUFAs
ratio on admission has been shown to predict neurological de-
terioration (Suda 2013). In patients on a low-dose statin ther-
apy, administration of EPA reduced the risk of a recurrent stroke
(Tanaka 2008). Marine-derived n-3 PUFAs are suggested to reduce
inflammation, improve endothelial activity, and decrease platelet
aggregation (Calder 2012a; Calder 2012b). The antithrombotic
effects of marine-derived n-3 PUFAs include reducing thrombin
formation, decreasing oxidative stress (Gajos 2011), and increas-
ing plaque stability (Thies 2003).
Recent findings from animal models showed that unesterified
DHA injection or infusion with fish oil within three hours af-
ter brain ischaemia reduced total infarct volume by 51% in rats
(Belayev 2009), and by 36% in mice (Zhang 2014), compared
to placebo. It also significantly improved functional outcome af-
ter cerebral ischaemia in both models. In a rat model, DHA ad-
ministration up to five hours after focal ischaemia increased neu-
robehavioural recovery, reduced brain infarction and oedema, and
activated neuroprotectin D1 (NPD1) synthesis in the penum-
bra (Belayev 2011). NPD1 is a lipid mediator, synthesised from
DHA, which stimulates cell-protecting and pro-survival signalling
(Belayev 2011), and seems to have a role in neuroprotection
(Calder 2012a). NPD1 suppresses apoptosis (Bazan 2005), and
promotes neurogenesis (Eady 2014). Additionally, DHA exerts
an anti-inflammatory effect during ischaemic injury through the
attenuation of microglia activation in both young and aged rat
models (Belayev 2011; Eady 2014; Hong 2014; Zendedel 2015).
Marine-derived n-3 PUFAs treatment in rats also attenuated the
death of both neurons and astrocytes, with the latter being essential
for neuronal survival (Belayev 2011). The supplementation with
n-3 PUFAs-enriched fish oil for three months before and up to one
month after stroke in mice stimulated the expression of angiopoi-
etins (ANGPTs 1 and 2), and improved the migration and survival
of neuroblasts (Zhang 2015). Myelin integrity was also preserved
and oligodendrogenesis was promoted after ischaemia, facilitating
therefore the recovery of white matter and neurological functions
(Zhang 2015). Transgenic fat-1 mice, which overproduce n-3 PU-
FAs, have been shown to have long-term behavioural and histolog-
ical protection against transient focal cerebral ischaemia, exhibit-
ing improvements in revascularisation and angiogenesis compared
to wild-type littermates (Wang 2014). Taken together, these re-
sults suggest that marine-derived n-3 PUFAs may be beneficial not
only in the acute phase but also for long-term functional recovery
after cerebral ischaemia.
With respect to the risk of haemorrhagic stroke, evidence assess-
ing the impact of marine-derived n-3 PUFAs intake shows con-
flicting results. Early epidemiological studies in Greenlandic Eski-
mos (or Inuit) observed a positive relationship between increased
fish intake and incidence of haemorrhagic stroke (Dyerberg 1979;
Ostergaard Kristensen 1983). This effect is likely due to the EPA
component of fish oil, which at high doses inhibits platelet aggre-
gation (Jakubowski 1979). However, an augmented incidence of
cerebral haemorrhage was not observed in later studies in women
with high consumption of fish and n-3 PUFAs (Iso 2001), nor in
patients using fish oil or EPA supplements (Nakase 2015; Pryce
2016).
Why it is important to do this review
Given that stroke is one of the main causes of long-term disability
worldwide (Mozaffarian 2016), it is critical to examine the estab-
lished and potential approaches to protecting the brain during the
crucial period of damage and recovery. If marine-derived n-3 PU-
FAs supplements were shown to reduce cerebral ischaemia severity
or improve recovery without increasing the risk of cerebral haem-
orrhage, this would provide a safe, inexpensive, and simple inter-
vention which is easy to implement. Some studies looking at ma-
rine-derived n-3 PUFAs supplementation and human stroke have
been reported. One non-randomised study of stroke patients al-
ready taking EPA found no increased risk of haemorrhage but was
underpowered for recurrent events (Nakase 2015), while a sub-
analysis of the Japan EPA Lipid Intervention Study (JELIS) found
reduced risk of recurrent stroke in patients also taking low-dose
statin (Tanaka 2008). A study using a guideline-recommended
moderate dose of fish oil supplement (0.7 g DHA daily) or placebo
on cardiovascular biomarkers, mood- and health-related quality
of life in patients with a history of ischaemic stroke found no ef-
fect after 12 weeks’ supplementation (FOILS). Heterogeneity in
results might be related to variation in doses or intervention time,
different pathophysiologies of the clinical outcomes (Mozaffarian
2006), and the potential oxidation of the fish oils (FOILS). The
effects of administration of marine-derived n-3 PUFAs are also
likely to differ according to the type of stroke: therefore, assessing
their impact on total stroke risk might underestimate the strength
of the real association with a specific type of stroke (Kris-Etherton
2002; Zhang 1999).
No systematic review looking specifically at the effect of ma-
rine-derived n-3 PUFAs as a treatment for stroke has been pub-
lished to date. Some systematic reviews of randomised controlled
trials have reported the effect of marine-derived n-3 PUFAs on
stroke incidence in populations with a history of cardiovascular
disease at baseline (Abdelhamid 2018; Chowdhury 2012). How-
ever, they did not explore the outcomes considering only partici-
pants with previous stroke. Another recent meta-analysis reported
a composite of major cardiovascular events following marine-de-
rived n-3 PUFAs intervention in participants with prior stroke
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without, however, specifically addressing the recurrence or recov-
ery from stroke (Aung 2018). This Cochrane Review combines
and summarises the available outcome evidence from human ran-
domised studies of administration of marine-derived n-3 PUFAs
after stroke.
O B J E C T I V E S
To assess the effects of administration of marine-derived n-3 PU-
FAs on functional outcomes and dependence in people with stroke.
Our secondary outcomes were vascular-related death, recurrent
events, incidence of other type of stroke, adverse events, quality of
life, and mood.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of adminis-
tration of marine-derived n-3 PUFAs after stroke onset, versus
placebo or open control (no placebo), regardless of time lapse be-
tween onset and intervention, language, and blinding design. We
excluded quasi-randomised, non-randomised, and observational
studies.
Types of participants
We included all participants with a diagnosis of stroke (including
TIA) on the basis of clinical examination findings, diagnostic test
results, or according to the definitions used by researchers to enrol
participants in their studies, regardless of severity, comorbidities,
age, gender, and phase of the disease (from acute to chronic). We
included trials with mixed populations in the analysis when they
met our inclusion criteria and separate data for stroke patients
were available.
Types of interventions
We included trials comparing administration of marine-derived n-
3 PUFAs regardless of duration, dosage, route of administration,
or type (fatty acids supplements, marine oils or fish intake) with
placebo or no intervention. Eligible interventions included but
were not limited to: fish oil, krill oil, microalgae oil, cod liver oil,
other marine oils, EPA and/or DHA ethyl esters, and consumption
of fish (such as salmon, mackerel, tuna, trout, sprat, pilchard,
herring, sardine, swordfish).
We excluded trials in which only one of the groups (treatment
or control) received another active therapy. However, we included
trials where the addition of marine-derived n-3 PUFAs to another
treatment was compared to the other treatment alone, therefore
assessing the effect of marine-derived n-3 PUFAs independently.
Types of outcome measures
Primary outcomes
The primary outcome was efficacy (functional outcome or disabil-
ity/dependency) for the latest time point of assessment, using a val-
idated scale (e.g. modified Rankin Scale (mRS); Barthel index (BI);
or change in National Institutes of Health Stroke Scale (NIHSS)).
For studies using multiple scales, we included all functional out-
come and disability/dependency measures reported. However, for
a meta-analysis we would have selected the one with the largest
amount of data available or, in the case of equal amounts of data,
the one reported first in the study.
Secondary outcomes
We assessed the secondary outcomes as follows: after a short follow-
up (up to three months), and after a longer follow-up (over three
months).
• Vascular-related death.
• Recurrent events: fatal or non-fatal (same type of stroke, i.e.
ischaemic or haemorrhagic).
• Incidence of other type of stroke (ischaemic or
haemorrhagic): fatal or non-fatal.
• Adverse events: nausea, vomiting, allergic reaction, or other
serious adverse events associated with the intervention.
• Quality of life (scales defined by authors).
• Mood (scales defined by authors).
Search methods for identification of studies
See Cochrane Stroke’s search methods for full search strategies and
a list of other resources searched. We searched for trials in all
languages and arranged for the translation of relevant articles where
necessary.
Electronic searches
We searched the Cochrane Stroke Group trials register and the
following electronic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 1 of 12, January 2019) in the Cochrane
Library (Appendix 1).
• MEDLINE Ovid (from 1948 to 6 August 2018) (Appendix
2).
• Embase Ovid (from 1980 to 6 August 2018) (Appendix 3).
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• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; from 1982 to 06 August 2018)
(Appendix 4).
• Science Citation Index Expanded - Web of Science (SCI-
EXPANDED), searched on 6 August 2018 (Appendix 5).
• Conference Proceedings Citation Index-Science - Web of
Science (CPCI-S), searched on 6 August 2018 (Appendix 5).
• BIOSIS Citation Index, searched on 6 August 2018
(Appendix 5).
We developed the MEDLINE search strategy (Appendix 2) with
the help of the Cochrane Stroke Group Information Specialist and
adapted it for the other databases.
We also searched the following ongoing trial registers.
• US National Institutes of Health Ongoing Trials Register (
clinicaltrials.gov), searched on 6 August 2018 (Appendix 6).
• Stroke Trials Registry ( strokecenter.org/trials), searched on
28 January 2019 (Appendix 7).
• ISRCTN Registry ( isrctn.com), searched on 28 January
2019 (Appendix 8).
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( who.int/ictrp/en), searched
on 6 August 2018 (Appendix 9).
Searching other resources
In order to identify other published, unpublished, and ongoing
studies we:
• checked the bibliographies of included studies and any
relevant systematic reviews identified for further references to
relevant trials;
• used the Science Citation Index Reference Search for
forward tracking of included trials;
• contacted researchers in the field to obtain additional
information on relevant trials;
• contacted original authors for clarification and further data
when trial reports were unclear.
Data collection and analysis
Selection of studies
Two review authors (CGAC, and MJM or FT) independently
screened titles and abstracts of the references obtained as a result
of our searching activities and excluded obviously irrelevant re-
ports. We retrieved the full-text articles for the remaining refer-
ences and two review authors (CGAC, and MJM or FT) inde-
pendently screened the full-text articles and identified studies for
inclusion, and identified and recorded reasons for exclusion of the
ineligible studies. We resolved any disagreements through discus-
sion or, if required, we consulted a third review author. We col-
lated multiple reports of the same study so that each study, not
each reference, is the unit of interest in the review. We recorded
the selection process and completed a PRISMA flow diagram.
Data extraction and management
Two review authors (CGAC, and FT or MJM) independently ex-
tracted data from included studies. Information extracted included
study settings, time frame, type of event, type of intervention,
as well as dose and mode of delivery, participants’ characteristics,
dietary information, outcomes reported, and trial authors’ defi-
nitions. We resolved discrepancies by discussion or consultation
with a third review author.
Assessment of risk of bias in included studies
Two review authors (CGAC, and FT or MJM) independently as-
sessed risk of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We resolved any disagreements by discussion or by involv-
ing another review author. We assessed risk of bias considering the
following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded the risk of bias for each domain as high, low, or unclear
and provided information from the study report together with a
justification for our judgement in the ’Risk of bias’ tables.
Measures of treatment effect
For continuous outcomes we calculated the mean difference (MD)
with 95% confidence intervals (CI) for data measured in the same
way between trials. We planned to calculate standardised mean
difference (SMD) with 95% CI in case different scales were used
for measurement; however, due to the small number of studies
assessing continuous outcomes, this was not necessary. For binary
outcomes, we calculated the risk ratios (RR) with 95% CI.
Unit of analysis issues
The unit of analysis in all trials was individual participants. For
studies where there was more than one follow-up period, we in-
cluded the longest period recorded to extract outcome data. For
non-fatal recurrent events, we planned to only record the first event
of each participant. We considered the inclusion of studies with
non-standard designs (e.g. cross-over trials, cluster randomised tri-
als) following the guidance in Chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
10Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dealing with missing data
We contacted study authors to request any missing data. We
planned to consider the guidelines from the Cochrane Handbook
for Systematic Reviews of Interventions for data imputation if nec-
essary (Higgins 2011).
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each meta-analysis, with a value above 50% indicating substan-
tial heterogeneity. We explored the reasons for heterogeneity and
identified if there were clinical or methodological explanations for
differences in treatment effects between studies.
Assessment of reporting biases
As only nine trials in this systematic review contributed any data,
we assessed reporting bias qualitatively on the basis of character-
istics of included trials.
Data synthesis
Where we considered that studies could be combined, we con-
ducted random-effects model meta-analysis by pooling the ap-
propriate data using Review Manager 5 (Review Manager 2014).
When this was not possible, we summarised the results in a nar-
rative manner, including text, figures, and tables.
GRADE and ’Summary of findings’ tables
We created ’Summary of findings’ tables (Summary of findings
for the main comparison; Summary of findings 2) to compare the
administration of marine-derived n-3 PUFAs versus placebo or no
intervention after both a short (up to three months) and a longer
(over three months) follow-up, using the following outcomes: ef-
ficacy, vascular-related death, recurrent events, incidence of other
type of stroke, adverse events, quality of life, and mood. We used
the five GRADE considerations (study limitations, consistency of
effect, imprecision, indirectness, and publication bias) to assess the
quality of a body of evidence as it relates to the studies that con-
tribute data to the review for the prespecified outcomes (Atkins
2004). We used methods and recommendations described in Sec-
tion 8.5 and Chapter 12 of the Cochrane Handbook for Systematic
Reviews of Interventions ( Higgins 2011), and used GRADEpro
GDT software (GRADEpro GDT). We justified all decisions to
downgrade the quality of studies using footnotes, and we made
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
We originally planned to carry out subgroup analyses based on type
of stroke (ischaemic or haemorrhagic), dose, type of intervention
(fatty acids supplements, marine oils or fish intake), length of
intervention (up to three months and over three months), and
initial time of intervention (up to three months and over three
months from event onset). However, there were not sufficient data
available for subgroup analysis.
Sensitivity analysis
We originally planned to perform sensitivity analyses by excluding
the trials with overall high risk of bias, and excluding studies with
substantial missing data. However, due to the small number of
studies with available outcome data, sensitivity analysis was not
appropriate.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded 4930 records after removing dupli-
cates and we identified 4362 additional references through other
sources, including Science Citation Index Reference Search, sys-
tematic reviews, and references lists (Figure 1). We screened a to-
tal of 9292 records of which 8766 were excluded from the titles
and abstracts. We assessed the remaining 526 records in full. From
these, we identified 29 completed randomised controlled trials
(RCTs) eligible for inclusion. Additionally we identified six more
studies that need clarification for inclusion, and three ongoing tri-
als.
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Figure 1. Study flow diagram.
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Included studies
A total of 29 studies were eligible for our review (Characteristics of
included studies). However, in 22 studies the stroke/TIA partici-
pants were only a proportion of the study population; and three tri-
als, which fully included stroke/TIA patients, did not report rele-
vant outcomes for the review. We attempted to contact the authors
of the 29 studies for more information and relevant outcome data
on stroke/TIA population. Twelve study authors replied, and five
provided additional data (ALPHA OMEGA; GISSI HF; OPAL;
Risk & Prevention Study; Saito 2017).
Consequently, only nine studies have available data specifically
in stroke/TIA populations for at least one outcome of the re-
view. Of these studies, three had a follow-up no longer than three
months (FOILS; Foroughinia 2018; Saito 2017), and the other
six had a longer follow-up (ALPHA OMEGA; GISSI HF; JELIS;
NUTRISTROKE; OPAL; Risk & Prevention Study). All stud-
ies in the short follow-up included only participants with prior
stroke/TIA, whereas for the longer follow-up in all except one
(NUTRISTROKE), stroke/TIA participants constituted a small
proportion of their study population.
Sample characteristics
The nine studies providing data for the review involved a total of
3339 participants with stroke or TIA, or both, and consisted of
1954 men and 1385 women. The age of the participants ranged
from a median of 48 years (Saito 2017), to an average of 75.2 years
(Foroughinia 2018). Only one study included participants in the
acute phase of stroke (Saito 2017). Three studies included partic-
ipants with previous ischaemic stroke only (FOILS; Foroughinia
2018; NUTRISTROKE), one with previous subarachnoid haem-
orrhage only (Saito 2017), one with both ischaemic and haem-
orrhagic stroke (JELIS), and the remaining trials did not specify
type of baseline stroke (Table 1). One study was stopped early due
to haemorrhagic transformation in two participants (Foroughinia
2018).
Interventions
On the short follow-up, one study provided fish oil capsules
(FOILS), one a combination of intravenous fish-oil-based lipid
emulsion and ethyl ester capsules (Saito 2017), and the third one
just described the intervention as omega-3 fatty acids soft gel cap-
sules (Foroughinia 2018). Doses ranged from 1.2 g/day to approx-
imately 3.3 g/day of EPA and DHA. Only one of these studies
was placebo-controlled (FOILS), and length of intervention varied
across studies from a single dose (Foroughinia 2018), to 12 weeks
(FOILS). One study included anticoagulants and antiplatelets as
co-interventions (Foroughinia 2018) (Table 2).
Across the studies with a longer follow-up, four trials provided
ethyl ester capsules, three of them included both EPA and DHA
(GISSI HF; OPAL; Risk & Prevention Study), and one only EPA
(JELIS). One study used fish oil capsules (NUTRISTROKE), and
one a margarine supplemented with EPA and DHA (ALPHA
OMEGA). Doses were between 400 mg and 1800 mg of marine-
derived n-3 PUFAs. All the studies except one - JELIS - were
placebo controlled and length of intervention ranged from 12
months to more than five years. Two studies had a 2 × 2 facto-
rial design (ALPHA OMEGA; NUTRISTROKE), with ALA and
antioxidants, respectively, as the additional intervention; in one
study, participants were also randomised to statins or correspond-
ing placebo (GISSI HF); and in another all participants were on
statins therapy (JELIS) (Table 2).
Outcomes
Efficacy - our primary outcome - was reported in two studies. One
study had a short follow-up and used the Glasgow Outcome Scale
Extended (GOSE), the results being reported as a dichotomised
outcome (poor or good clinical outcome) (Saito 2017). The other
study reported our primary outcome as both Barthel Index and
Rivermead Mobility Index and the latest time point of assessment
was 12 months (NUTRISTROKE).
Vascular-related death was reported in seven studies: two with
short (FOILS; Saito 2017), and five with long follow-up (
ALPHA OMEGA; GISSI HF; NUTRISTROKE; OPAL; Risk
& Prevention Study). Some information on recurrent events was
available for one study in the short follow-up (Foroughinia 2018),
and for all studies except NUTRISTROKE with longer follow-
up. Incidence of other type of stroke could only be assessed in two
studies (Foroughinia 2018; Saito 2017), because most of the stud-
ies did not state the type of index stroke (Table 1). Information
regarding adverse events was available in two studies with short
follow-up (Foroughinia 2018; Saito 2017), and one with longer
follow-up (Risk & Prevention Study). Quality of life, assessed as
SF-36 questionnaire (with physical and mental components sepa-
rately), was reported only in one study (FOILS). Mood assessment
was available in two studies (FOILS; OPAL), one in each follow-
up category. Assessment was performed using 28-item General
Health Questionnaire (GHQ) in one study (FOILS), and 30-item
GHQ in the other one (OPAL).
Excluded studies
After assessing full-text reports, we excluded 353 studies from this
systematic review (see Figure 1 and Characteristics of excluded
studies). The most frequent reasons for exclusion were no indi-
cation of stroke/TIA in baseline characteristics of the participants
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and no randomised controlled trial design (including studies that
used a quasi-randomised method of allocation).
Risk of bias in included studies
We assessed risk of bias in the 29 studies included in the review
(see Figure 2 and Figure 3). However, considering that 20 of those
studies do not have outcome data available for stroke/TIA partic-
ipants only, we provided information regarding each domain for
all included studies, and in more detail for the nine studies that
are contributing data to the review (ALPHA OMEGA; FOILS;
Foroughinia 2018; GISSI HF; JELIS; NUTRISTROKE; OPAL;
Risk & Prevention Study; Saito 2017). We include supporting in-
formation for our judgement about the methodological quality of
the studies in Characteristics of included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We considered 22 studies to have adequate random sequence gen-
eration and 16 studies described appropriate allocation conceal-
ment; the remaining studies were ’unclear’.
From the studies providing outcome data, eight had a low risk
regarding random sequence generation and one study was unclear.
Two studies did not describe allocation concealment methods and
we therefore classified them as ’unclear’. We assessed the rest of
studies as having a low risk of selection bias (Figure 2).
Blinding
We considered open-label trials (seven studies) as having high risk
for performance bias; 18 studies provided enough details about
blinding for us to consider them at low risk of bias; and the rest
of the studies were at unclear risk of bias (Figure 2).
From the subgroup that is contributing data to the review,
three were open-label, assessed as high risk of performance bias
(Foroughinia 2018; JELIS; Saito 2017); one was unclear (FOILS);
and we considered the remainder to have a low risk of bias (Figure
2).
Regarding detection bias 15 studies, six of them providing data for
the review, had a low risk of bias (Figure 2). Two trials, including
one that has available outcome data (Foroughinia 2018), had a
high risk of detection bias, and the rest were unclear (Figure 2).
Incomplete outcome data
We identified one study with a high risk of attrition bias (Green
1985). This trial, which did not contribute data to the review, had
a high rate of dropouts and it provided baseline and outcome data
only from participants that completed the study. We deemed 21
studies, including six with relevant outcomes, as having a low risk
of bias, and the rest were unclear (Figure 2).
Selective reporting
We considered two studies as having a high risk of selective report-
ing bias, including one with a relevant review outcome (OPAL).
Four studies, three of them providing outcome data (ALPHA
OMEGA; GISSI HF; Risk & Prevention Study), had enough in-
formation available for us to consider them at low risk of reporting
bias, and the remainder of the studies were unclear (Figure 2).
Other potential sources of bias
We considered one study as having a high risk of other bias because
in the trial registration, ’stroke’ is stated as an exclusion criterion;
however, participants with a self-reported history of stroke were
included in the report (Zhang 2017). We classified six studies, in-
cluding one that provided data for the review (NUTRISTROKE),
at unclear risk of bias, due to concerns about various aspects of
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study design or conduct, or both. We did not detect other poten-
tial sources of bias in the remaining studies.
Effects of interventions
See: Summary of findings for the main comparison Marine-
derived n-3 fatty acids therapy compared to No marine-derived
n-3 fatty acids therapy for stroke. Short follow-up (three months
or less); Summary of findings 2 Marine-derived n-3 fatty acids
therapy compared to No marine-derived n-3 fatty acids therapy
for stroke. Follow-up longer than three months
Marine-derived n-3 PUFAs therapy for stroke: short
follow-up (up to three months)
See Summary of findings for the main comparison
Efficacy (functional outcome or disability/dependency):
primary outcome
There is very low quality evidence of a lack of effect of marine-de-
rived n-3 PUFAs therapy for subarachnoid haemorrhage on clin-
ical outcome (RR 0.78, 95% CI 0.36 to 1.68, P = 0.52). Only
one study reported this outcome (Saito 2017). It was assessed by
Glasgow Outcome Scale Extended (GOSE) and reported as a bi-
nary outcome. The sample size was very small (40 participants),
and clinical outcome was not the primary aim of the trial, as this
was a pilot study to assess feasibility.
Vascular-related death
Two studies reported vascular-related death (FOILS; Saito 2017).
However, we considered a meta-analysis not to be appropriate
due to the small sample size and differences in study populations.
One study was carried out in participants with prior subacute and
chronic ischaemic stroke (FOILS), and the other study in people
with acute subarachnoid haemorrhage (Saito 2017). Both studies
tended to show a beneficial but non-significant effect (Analysis
1.2), but we graded the quality of evidence as low, with very se-
rious imprecision issues, as evidenced by small sample size and
wide confidence intervals crossing null effect, as well as important
benefit and important harm.
Recurrent events
Recurrent events were defined as the same type of stroke as the in-
dex event. One study provided very low quality evidence of no ef-
fect of marine-derived n-3 PUFAs on recurrent events (ischaemic
stroke), with a non-significant reduction in risk (RR 0.41, 95%
CI 0.02 to 8.84, P = 0.57) in a very small sample (18 participants)
(Foroughinia 2018). The study had high risk of bias and consid-
erable imprecision (Analysis 1.3).
Incidence of other type of stroke (ischaemic or
haemorrhagic)
Two studies reported incidence of other type of stroke (non-fa-
tal); however, each one had a different index stroke type. There-
fore, only one study reported incidence of haemorrhagic stroke
in participants who previously had ischaemic stroke (Foroughinia
2018), and one reported ischaemic events in participants with pre-
vious subarachnoid haemorrhage (Saito 2017). One trial tended
to favour the intervention (Saito 2017), and the other to favour
control (Foroughinia 2018); however, in both cases effect was not
statistically significant and the quality of the evidence is very low
due to imprecision and considerable risk of bias of one of the stud-
ies (Analysis 1.4).
Adverse events
There is very low quality evidence of a lack of effect on adverse
events (Analysis 1.5). One small study reported extracranial haem-
orrhage (RR 0.25, 95% CI 0.04 to 1.73, P = 0.16) (Foroughinia
2018), and the quality of evidence was downgraded due to risk of
bias and imprecision (Analysis 1.6). Another study reported low-
quality evidence on bleeding complications (RR 0.32, 95% CI
0.01 to 7.35, P = 0.47) (Saito 2017), and was also downgraded
due to imprecision (Analysis 1.7).
Quality of life
Health-related quality of life was reported by one study using
the SF-36 questionnaire (physical and mental component scales)
(FOILS) (Analysis 1.8). A higher SF-36 score indicates better
health-related quality of life; however, no information about the
scoring system used was available. The authors reported mean
change from baseline; despite the lack of significant effect, the di-
rection pointed to favour the placebo group. We graded the ev-
idence as low quality, due to imprecision and the fact that the
sample size might be too small for the sensitivity threshold of the
tool (Ware 1993).
Mood
One study reported mood, assessed with the 30-item General
Health questionnaire (GHQ-30) (FOILS). A higher GHQ score
is worse; however, no additional information about the scoring
system used or assessors was available. The study reported mean
change from baseline favouring control (MD 1.41, 95% CI 0.07
to 2.75, P = 0.04; 102 participants). We considered this evidence
as low quality, due to imprecision and unclear scoring system used.
Marine-derived n-3 PUFAs therapy for stroke: longer
follow-up (more than three months)
See Summary of findings 2
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Efficacy (functional outcome or disability/dependency):
primary outcome
One study reported efficacy at 12 months, measured with Barthel
Index score (scale from 0 to 100, higher score is better) for activi-
ties of daily living and Rivermead Mobility Index (scale from 0 to
15, higher score is better) for mobility (NUTRISTROKE). The
study authors found no effect of marine-derived n-3 therapy for
functional outcome (Barthel Index MD 7.09, 95% CI −5.16 to
19.34, P = 0.26; and Rivermead Mobility Index MD 1.30, 95%
CI −1.31 to 3.91, P = 0.33; Analysis 2.1 and Analysis 2.2, respec-
tively). However, we considered the quality of the evidence as very
low, due to risk of bias (unclear randomisation, allocation conceal-
ment, and attrition, as the number of participants completing the
trial was 60% higher in the intervention group (n = 32) compared
to the control group (n = 20)), and imprecision, considering that
the 95% CIs cross both null effect and important benefit.
Vascular-related death
On the longer follow-up, five studies similar enough to be pooled
in a meta-analysis reported vascular-related death. They provided
low-quality evidence of no effect with marine-derived n-3 PUFAs
(RR 1.02, 95% CI 0.78 to 1.35, P = 0.86) (Analysis 2.3; Figure 4).
Reasons for downgrading the evidence were related to imprecision,
due to small number of total events and 95% CIs crossing both
null effect and appreciable potential harm.
Figure 4. Forest plot of comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-
derived n-3 fatty acids therapy: follow-up longer than 3 months, outcome: 2.3 Vascular-related death.
Recurrent events
Most studies with a longer follow-up that reported recurrent events
did not state the type of baseline stroke in their population, or
did not provide separate information on recurrence by type of
index stroke. Therefore, our results include both ischaemic and
haemorrhagic strokes. Three studies reported all recurrent events
(fatal and non-fatal) (GISSI HF; JELIS; Risk & Prevention Study).
However, they were very heterogeneous (I² = 74%) and it was
not appropriate to pool their results (Figure 5). Furthermore, the
direction of the effects varied across studies. GISSI HF reported
a greater risk of recurrent events with marine-derived n-3 PUFAs
(RR 2.42, 95% CI 1.02 to 5.74, P = 0.04), whereas JELIS showed
a reduced risk (RR 0.65, 95% CI 0.42 to 0.99, P = 0.05). The
Risk & Prevention Study found no effect (RR 1.07, 95% CI 0.60
to 1.88, P = 0.83), with a 95% CI that crosses both null effect and
important potential harm. Because of these reasons we considered
the quality of the evidence as very low, due to imprecision and
inconsistency.
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Figure 5. Forest plot of comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-
derived n-3 fatty acids therapy. Follow-up longer than 3 months, outcome: 2.3 All recurrent events (fatal and
non-fatal). Subtotals only, studies not combined due to important heterogeneity (I² = 74%).
When considering only fatal events, we were able to conduct a
meta-analysis for the three studies that reported that outcome
(ALPHA OMEGA; OPAL; Risk & Prevention Study). We found
low-quality evidence of no effect of marine-derived n-3 PUFAs on
fatal recurrent stroke (RR 0.69, 95% CI 0.31 to 1.55, P = 0.37)
(Analysis 2.5), downgraded by imprecision.
There is low-quality evidence for non-fatal recurrent events, re-
ported by only one study, with a non-significant trend (RR 0.68,
95% CI 0.35 to 1.34, P = 0.27) (Risk & Prevention Study).
Incidence of other type of stroke (ischaemic or
haemorrhagic)
There was no information available for incidence of other type of
stroke with a follow-up longer than three months.
Adverse events
There is low-quality evidence of no effect for adverse events (RR
0.94, 95% CI 0.56 to 1.58, P = 0.82), reported by only one
study (Risk & Prevention Study). The quality of the evidence
was downgraded for imprecision due to small number of events
and very wide confidence intervals crossing null effect, appreciable
benefit, and appreciable harm.
Quality of life
No studies with a follow-up longer than three months reported
quality of life.
Mood
One study reported mood, assessed with 28-item General Health
questionnaire (GHQ-28) (OPAL). A higher GHQ score is worse;
however, no additional information about the scoring system used
or the assessors was available. The study showed no effect (MD
1.00, 95% CI −2.07 to 4.07, P = 0.61), reported by mean score
at latest follow-up; we regarded this evidence as low quality, con-
sidering the very small sample size and imbalance in groups.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy for stroke: follow-up longer than three months
Patient or population: stroke and/ or TIA
Setting: hospital, outpat ient, community or home
Intervention: marine-derived n-3 fatty acids therapy
Comparison: no marine-derived n-3 fatty acids therapy
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Follow-up t ime: 5 years
39 per 1000 37 per 1000
(22 to 62)
Quality of lif e not
measured
- - - No studies reported




The mean mood was 1.
33
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Follow-up t ime: 2 years
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; MD: Mean dif ference; RR: Risk rat io; OR: Odds rat io; TIA: Transient ischaemic attack
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Unclear risk of bias and imbalanced groups. Downgraded 1 level
2 95% conf idence intervals cross null ef fect and appreciable benef it . Downgraded 1 level
3 Small sample size. Downgraded 1 level
4 Conf idence intervals cross both null ef fect and potent ial harm. Downgraded 1 level
5 Small number of total events. Downgraded 1 level
6 95% conf idence intervals cross null ef fect, and both appreciable benef it and harm. Downgraded 1 level
7 High risk of bias (imbalanced groups and report ing bias). Downgraded 1 level

























































































D I S C U S S I O N
Summary of main results
We identified 29 RCTs of marine-derived n-3 PUFAs that in-
cluded stroke or TIA participants, or both. From these, only nine
studies had available outcome data, involving a population of 3339
participants in total. The age of this population ranged from a
median of 48 years in Saito 2017 to an average of 75.2 years in
Foroughinia 2018. Three trials had a follow-up of three months
or sooner and six studies followed up the participants for longer
than three months. Only one study included participants in the
acute phase of stroke (subarachnoid haemorrhage). Doses of ma-
rine-derived n-3 PUFAs ranged from 400 to 3300 mg/day. Vari-
ous forms of delivery were also used: marine-derived n-3 PUFAs-
enriched margarine, fish oil, and ethyl esters of DHA and EPA.
One study also included an initial intravenous triglyceride emul-
sion load (Saito 2017).
We assessed the effect of the interventions on relevant outcomes
in two categories: studies with a follow-up up to three months;
and follow-up longer than three months. Efficacy was reported
in two studies, one in each follow-up category. Two trials in the
short follow-up and five in the longer one reported vascular-related
death. Recurrent events data, either fatal, non-fatal, or combined,
were available for one study in the short follow-up and five studies
in the long follow-up. Incidence of other type of stroke could be
assessed in two studies (one of each type of stroke). Adverse events
data were available in two studies of the short follow-up and one
of the longer follow-up. One study assessed health-related quality
of life and two trials reported mood as well.
It was not possible to pool the results in meta-analyses, except
for vascular-related death (RR 1.02, 95% CI 0.78 to 1.35) and
fatal recurrent events (RR 0.69, 95% CI 0.31 to 1.55) in the long
follow-up.
We found few significant effects regarding marine-derived n-3
PUFAs intervention. Mood, in short follow-up, favoured control
(MD 1.41, 95% CI 0.07 to 2.75) with a single study providing
low-quality evidence (FOILS). Two individual studies reported
recurrence (fatal and non-fatal combined) in the long follow-up
with different direction of effect (GISSI HF: RR 2.42, 95% CI
1.02 to 5.74; and JELIS: RR 0.65, 95% CI 0.42 to 0.99). A third
study reported no effect for the same outcome (Risk & Prevention
Study: RR 1.07, 95% CI 0.60 to 1.88); therefore, quality of the
evidence was very low due to inconsistency and imprecision.
There was a lack of effect of the intervention in the rest of the
outcomes, with the quality of the evidence ranging from low to
very low. Incidence of other type of stroke and quality of life
were not reported in studies with a follow-up of more than three
months.
Overall completeness and applicability of
evidence
Of a considerable number of studies addressing intervention with
marine-derived n-3 PUFAs in cardiovascular diseases, only 29
studies fulfilled all our inclusion criteria and, from these, only nine
had available outcome data for stroke population. Most studies
did not state the time between the baseline event and start of the
intervention. Those which reported such information had partic-
ipants in different stages (acute, subacute, and chronic) making it
difficult to apply the evidence in a practical level, due to the differ-
ent potential mechanisms of marine-derived n-3 PUFAs therapy
post-stroke.
Only three studies with short follow-up (FOILS; Foroughinia
2018; Saito 2017), and one with a longer follow-up (
NUTRISTROKE) had a study population entirely of stroke or
TIA participants, or both. The rest of the studies comprised a
mixed population, which rendered a very small number of partic-
ipants with the condition of interest, making the generalisation of
the results not possible.
We originally planned to use funnel plots to assess publication
bias. However, this was not possible due to the small number of
trials providing outcome data to the review. Through our searches
of trial registers we identified three studies seemingly eligible for
the review but the results have yet to be published and we could
not contact the investigators for clarification. As only nine studies
provided data, those three trials, if carried out, represent an im-
portant fraction of the evidence that remains unpublished.
Only two studies addressed the primary outcome of the review
(efficacy, as functional outcome or disability/dependency), and
only one of these was performed in acute stroke (subarachnoid
haemorrhage) (Saito 2017). However, being a pilot study, it was
underpowered for efficacy. We did not find adequately controlled
studies conducted in acute ischaemic stroke.
Different scales were used to assess functionality (Glasgow Out-
come Scale Extended, Barthel Index, and Rivermead Mobility In-
dex). While modified Rankin Scale and Barthel Index are most fre-
quently used for measuring acute stroke outcome, there is still no
consensus regarding the most robust assessment. Updates of this
review should take into consideration future recommendations in
this area (Broderick 2017).
Another aspect that makes the generalisation and applicability of
the evidence difficult is the variation in the form of administering
the intervention. Forms of delivery included fish oil capsules, ethyl
ester capsules, fish-oil-based intravenous emulsion, and margarine
enriched with EPA and DHA derived from fish oil. The bioavail-
ability, and therefore potentially the efficacy, of marine-derived n-
3 PUFAs varies according to the type of lipid vector, tending to
be more bioavailable when delivered in phospholipids, followed
by re-esterified triglycerides, triglycerides, and then ethyl esters
(Cholewski 2018). Bioavailability can be further determined by
the site of esterification of EPA and DHA on the glycerol back-
bone in phospholipids and triglycerides, and is also influenced by
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the presence of other lipids that facilitate the formation of micelles
in the intestinal lumen and improve digestion and absorption rate
(Cholewski 2018).
Quality of the evidence
We considered the quality of the evidence low or very low for
each outcome assessed. We found imprecision of the evidence in
most outcomes, due to small number of studies assessing them,
few total events, and small sample sizes that were, in most cases,
subpopulations of larger trials. Risk of bias, especially among the
smaller trials, was also a reason for downgrading the quality of the
evidence. We did not consider the quality of the evidence high or
moderate for any outcome.
Potential biases in the review process
We conducted the electronic searches without language and date
restrictions and we made every effort to identify all relevant stud-
ies. Considering the population of interest (stroke patients) it is
likely that most trials carried out are listed in clinical trial regis-
ters or primary databases. Nevertheless, our cited reference search
allowed us to gather smaller-scale studies that might have been
overlooked otherwise. There were a few studies overdue for publi-
cation and we attempted unsuccessfully to contact study authors
for clarification; therefore, there is a small possibility that these
trials have been carried out and remain unpublished. When we
suspected that a trial might have some participants with a history
of stroke/TIA, we contacted the authors to request more infor-
mation; the response rate was low. We also identified older trials
whose primary outcomes were not relevant for our review and
where additional data were no longer available.
As marine-derived n-3 PUFAs are present in the diet, it was impor-
tant to consider baseline levels. Dietary information was mostly
mentioned briefly, and referred to a similar fish intake across groups
and a washout period in case participants were consuming n-3
PUFAs supplements before enrolment. However, not all studies
included dietary assessment. Due to the small amount of data
available, a sensitivity analysis with only the studies that took into
account baseline levels of n-3 PUFAs was not possible, but such
an analytical approach could be considered for future updates of
this review.
Agreements and disagreements with other
studies or reviews
To our knowledge, this is the first review specifically addressing the
effect of marine-derived n-3 PUFAs on functional outcomes after
stroke. With respect to our secondary outcomes, the only one for
which we found similar, although not identical, approaches was
recurrence.
Abdelhamid 2018 reported a higher risk of stroke with long-chain
omega-3 PUFAs for secondary prevention (RR 1.21, 95% CI 1.05
to 1.40). However, they included all participants that had a his-
tory of cardiovascular disease at baseline, not only stroke history
- they did not include JELIS and OPAL in that analysis, as both
studies were considered as primary prevention of stroke in that
review. Chowdhury 2012 reported no effect (RR 1.17, 95% CI
0.99 to 1.38) of long-chain omega-3 fatty acids on cerebrovascular
disease, also in a population with existing cardiovascular disease
at baseline, not specifically stroke. Our available data for all re-
current events (fatal and non-fatal) could not be pooled due to
the large heterogeneity (I² = 74%) across the studies that reported
them (GISSI HF; JELIS; Risk & Prevention Study). However, we
found different directions of effect, with one study favouring con-
trol, one favouring marine-derived n-3 PUFAs, and the third one
showing a null effect. For non-fatal recurrent events only, we only
had data available from one study (Risk & Prevention Study) (RR
0.68, 95% CI 0.35 to 1.34); and for fatal events we carried out
a meta-analysis with data from three studies (ALPHA OMEGA;
OPAL; Risk & Prevention Study) (RR 0.69, 95% CI 0.31 to 1.55).
In contrast with the results presented by Abdelhamid 2018 and
Chowdhury 2012, when considering only the participants with
stroke/TIA at baseline and non-fatal and fatal events separately,
the direction of the effect changed, even when non-significant. As
there were few events, small sample sizes, and inconsistency of re-
sults, the evidence for the stroke population should be considered
of low quality.
Chowdhury 2012 also reported some information on stroke-type
incidence (ischaemic or haemorrhagic), but this included all par-
ticipants in JELIS and GISSI HF, not only participants with prior
stroke.
In participants with prior stroke, Aung 2018 reported no effect of
marine-derived omega-3 PUFAs intervention on major vascular
events (RR 1.07, 95% CI 0.95 to 1.20). Although they included
only stroke population in their analysis, our results are not directly
comparable because they did not assess the effect of marine-derived
n-3 PUFAs in stroke recurrence only, but in a composite of vascular
events (first occurrence of non-fatal myocardial infarction or death
caused by coronary heart disease; non-fatal or fatal stroke; or any
revascularisation procedure).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is not sufficient high-quality evidence to indicate
therapy with marine-derived n-3 PUFAs after stroke. Only one
pilot study has looked at clinical outcome after acute subarachnoid
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haemorrhage and no properly controlled studies have looked at
acute ischaemic stroke.
Implications for research
Despite the large number of studies addressing marine-derived n-3
PUFAs intervention for cardiovascular diseases, there is only low-
quality evidence with respect to the stroke population. There is a
lack of studies addressing stroke recovery directly, especially during
the acute phase. Only a few studies with small sample sizes have
assessed vascular-related death, recurrence, adverse events, quality
of life, and mood in a population with a history of stroke or TIA,
or both. Adequately-powered studies are needed in haemorrhagic
stroke (specifically subarachnoid haemorrhage), considering that
the only data available were from a small pilot study. Additionally,
there have been no studies specifically addressing acute ischaemic
stroke, despite the preclinical evidence suggesting important ef-
fects in neuroprotection, especially within six hours from the is-
chaemic event. Future trials, both in ischaemic and haemorrhagic
stroke, should follow the CONSORT guidelines to ensure high
quality of evidence (Schulz 2010).
Studies assessing functionality might consider starting the inter-
vention as early as possible after the event, as well as using standard-
ised clinically-relevant measures for functional outcomes, such as
the modified Rankin Scale. Optimal doses remain to be deter-
mined; delivery forms (type of lipid carriers) and mode of admin-
istration (ingestion or injection) also need further consideration,
as only one acute study so far has used infusion of fish-oil-based
triglyceride emulsion, with potentially positive outcomes. With
regards to oral supplementation, besides the delivery forms in-
cluded in previous studies, future RCTs may contemplate the use
of a self-micro-emulsifying delivery system, which could improve
the rate of absorption and bioavailability (Qin 2017).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ALPHA OMEGA
Methods RCT; parallel; 2 × 2 factorial design
Number of study sites: 32
Dates: enrolment between April 2002 and December 2006, follow-up of 41 months
(average)
Participants Inclusion criteria: men and women aged 60 to 80 years; verified clinically diagnosed
myocardial infarction up to 10 years before randomisation; written informed consent
Exclusion criteria: living in a nursing home or other institution; participation in other
scientific study; habitual margarine intake < 10 g/day; habitual alcohol intake > 6 drinks
per day; use of fish oil capsules or other supplements containing n-3 fatty acids; presence
of cancer with < 1 year of life expectancy; cognitive impairment, as indicated by the
MMSE (score ≤ 21); unintended weight loss > 5 kg in the past year; lack of facilities
for cooled margarine storage at home; inability or unwillingness to comply with study
procedures
Sample size: 4837 participants (total population), 345 participants with history of stroke
Participants randomised to intervention group (only stroke population): 181 (92 to EPA-
DHA only and 89 to EPA-DHA + ALA)
Participants randomised to control group (only stroke population): 164 (83 to ALA only
and 81 to placebo)
Sex (only stroke population): EPA-DHA = 70 men and 22 women, EPA-DHA + ALA
= 69 men and 20 women, ALA = 65 men and 18 women, placebo = 60 men and 21
women
Age, years (only stroke population) mean ± SD: EPA-DHA = 70.95 ± 5.68, EPA-DHA
+ ALA = 69.92 ± 5.89, ALA = 70.34 ± 5.39, placebo = 70.38 ± 5.58
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: the Netherlands
Ethnicity: predominantly of Dutch origin
Interventions Comparison groups: 4 groups: EPA-DHA only, EPA-DHA and ALA, ALA only, and
placebo. This review collated the groups in 2: EPA-DHA (including EPA-DHA only
and EPA-DHA and ALA) versus no EPA-DHA (ALA only and placebo)
Intervention: average of 20 g/day of margarine supplemented with 400 mg of EPA-DHA
(derived from fish oil: Marinol®) or 400 mg of EPA-DHA + 2 g of ALA
Control: average of 20 g/day of margarine supplemented with 2 g of ALA or placebo
(oleic acid)
Compliance: amount of margarine tubs returned. Measurement of fatty acid composition
in plasma cholesteryl esters in random subgroups of 400 to 800 participants at baseline
and after 20 and 40 months of intervention
Duration of intervention: 40 months
Co-interventions: participants randomised also to ALA or placebo (as described above)
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ALPHA OMEGA (Continued)
Outcomes Primary outcome of study: major cardiovascular events
Relevant review outcomes measured (in total population): vascular-related death, recur-
rent events, adverse events
Available outcome data for stroke and/or TIA population only: vascular-related death,
fatal recurrent events (no data available in non-fatal recurrent stroke)
Latest time point of assessment: 6.5 ± 2.5 years
Withdrawals or exclusions, n (stroke and/or TIA population only): no withdrawals other
than death
Study authors’ contact status: replied data provided
Notes Dietary information: dietary data, including intake of different types of fish, collected
by a FFQ. For the total population, median intake of fish was 14 g/day (IQR 5 to 18 g/
day), and 12% of the participants never consumed fish. Participants were asked to avoid
n-3 fatty acids supplements during the trial
Funding: Netherlands Heart Foundation (grant no. 2000T401), US National Institutes
of Health (NIH/NHLBI and ODS, grant no. R01HL-076200) and Unilever R&D,
Vlaardingen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Simple randomization is applied,
using a randomization table (with a ran-
domization ratio of 1:1:1:1). The table was
produced on the computer by a random-
number generator before the start of the
trial“
Allocation concealment (selection bias) Low risk Quote: ”Treatment codes (A,B,C,D) are as-
signed by Unilever to four types of trial
margarine and are not known to others
involved in the trial. A table linking ran-
domization numbers to treatment codes is
stored in a safe, which is only accessible by
a third person who is not involved in the
Alpha Omega trial“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”All parties involved will be blinded
towards the type of intervention given to
the patients“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”Events were coded by three mem-
bers of the end-point adjudication com-
mittee, who were unaware of the identity
of the patient, the identity of the treating
physician, and the patient’s assigned study
group“
38Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ALPHA OMEGA (Continued)
Quote: ”Only events for which documen-
tation on the clinical diagnosis (e.g. hospi-
tal discharge records or letter) could be re-
trieved will be considered in the analysis“
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More participants discontinued margarine
in intervention group. Insufficient infor-
mation for discrepancy (”other“ or ”un-
known” reasons)
Selective reporting (reporting bias) Low risk Endpoints stated in the protocol
Other bias Low risk None detected
Doi 2014
Methods RCT; parallel; open label
Number of study sites: 1
Dates: between November 2010 and December 2012
Participants Inclusion criteria: acute MI patients treated with PCI within 24 hours of symptom onset
Exclusion criteria: cardiogenic shock; severe renal insufficiency requiring dialysis or con-
tinuous haemofiltration; cardiopulmonary arrest; emergent coronary artery bypass; and
failure of PCI
Sample size: 115 participants (total population), 14 participants with history of stroke
Participants randomised to intervention group (only stroke population): 7
Participants randomised to control group (only stroke population): 7
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Japan
Ethnicity: not stated
Interventions Comparison groups: EPA versus no intervention
Intervention: 1800 mg/day of EPA, no further details
Control: open label
Compliance: not stated
Duration of intervention: 30 days
Co-interventions: 2 mg/day of pitavastatin. Before PCI, 200 mg aspirin and 300 mg
clopidogrel. Intravenous heparin (10,000 IU) was administered after arterial access was
obtained and continued for 48 hours after angioplasty. Postprocedural antithrombotic
therapy: 100 mg/day and 75 mg/day clopidogrel
Outcomes Primary outcome of study: composite of death, reinfarction, stroke, ventricular fibrilla-
tion/ventricular tachycardia (within and after 48 hours), and paroxysmal atrial fibrilla-
tion
Relevant review outcomes measured (in total population): vascular-related death, recur-
rent events (stroke)
39Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Doi 2014 (Continued)
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 30 days
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: there were no significant differences in baseline plasma concentra-
tions of EPA and arachidonic acid before PCI
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation plan,
which included stratification by age and sex
Allocation concealment (selection bias) Unclear risk No details about concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Diagnosis was confirmed by an in-
vestigator who was blinded to treatment al-
location”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of participants in any group
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
EMPAR
Methods RCT; parallel; 2 × 2 factorial design
Number of study sites: 4
Dates: recruitment between June 1990 and June 1993, last follow-up in November 1993
Participants Inclusion criteria: a diagnostic coronary angiogram showing at least 1 localised coronary
artery stenosis of ≥ 50% reduction of lumen diameter by visual analysis and age ≥ 18
years
Exclusion criteria: certain characteristics of the coronary artery disease (culprit lesion
in a saphenous bypass graft, at the site of a previously dilated restenosis, or involving
the left main coronary artery; MI < 28 days previously, the presence of very unstable
angina necessitating PTCA in < 48 hours, or the presence of variant angina; or the
use of Sones’ approach); excessive bleeding risk (recent peptic ulcer or gastrointestinal
bleeding, platelets < 100000/mm³, predisposition to intracranial haemorrhage, or blood
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EMPAR (Continued)
pressure > 180/105 mmHg); concerns specific to the use of fish oils or LMWH (fish
product or LMWH allergy or hypersensitivity, a requirement for anticoagulant therapy,
the use of insulin, or significant hepatic or renal disease); or practical patient problems
(disease therapy that might interfere with LMWH action or evaluation; concomitant
disease likely to limit life span to < 6 months; drug or alcohol abuse; or insurmountable
geographic, social, or language barrier)
Sample size: 653 participants (total population), approximately 9 participants with his-
tory of stroke or TIA (reported as percentage of total population)
Participants randomised to intervention group (only stroke or TIA population): 6 or 7
(reported as 2% of total)
Participants randomised to control group (only stroke or TIA population): 3 (reported
as 1% of total)
Sex (only stroke or TIA population): not stated
Age (only stroke or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Canada
Ethnicity: not stated
Interventions Comparison groups: fish oil versus placebo (participants were subsequently randomised
to LMWH)
Intervention: fish oil capsules (maxEPA), each capsule containing 180 mg EPA and 120
mg DHA in the form of a triglyceride, 6 capsules given 3 times daily with meals (total,
5.4 g/day of marine-derived n-3 PUFAs)
Control: identical-appearing capsules of corn oil, 6 capsules given 3 times daily with
meals
Compliance: assessment method unclear
Duration of intervention: 4 months
Co-interventions: randomisation to LMWH (enoxaparin) 60 mg/day for 6 weeks or
standard therapy
Outcomes Primary outcome of study: reduction of PTCA restenosis
Relevant review outcomes measured (in total population): recurrent events (stroke),
adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 18±2 weeks
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: replied, no further data available
Notes Dietary information: none provided
Funding: Heart and Stroke Foundation of Ontario and Rhône Poulenc Rorer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information about random sequence
generation
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EMPAR (Continued)
Allocation concealment (selection bias) Unclear risk No details about allocation process
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information about blinding of partici-
pants or staff
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details in how outcomes were assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Discontinuation of medication was similar
across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Not enough data in some characteristics
(standard deviations not provided, percent-
ages given, not actual number of partici-
pants)
ESPRIT
Methods RCT; parallel; placebo-controlled
Number of study sites: 17
Dates: between March 1993 and May 1995
Participants Inclusion criteria: clinical indication for PTCA (angina or ischaemia not adequately
responsive to medical treatment or significant silent ischaemia after acute MI) in the
presence of at least 1 critical coronary artery stenosis (≥ 70% at visual inspection)
amenable to PTCA
Exclusion criteria: age < 18 years or > 75 years; recent (< 15 days) acute MI; the presence
of unstable disease not allowing the 4-week pretreatment before PTCA; culprit lesions in
the left main coronary artery, in a saphenous vein bypass graft, or in a previously dilated
site (restenotic lesions); excessive bleeding risk (recent peptic ulcer or gastrointestinal
bleeding, platelet count < 100,000/µL, and arterial hypertension not responsive to med-
ical treatment); contraindication to omega-3 fatty acids (such as allergy or hypersensi-
tivity to fish products); requirement for anticoagulant therapy; presence of significant
hepatic or renal disease; concomitant disease associated with limited life expectancy;
drug or alcohol abuse; or other factors (geographic location or language barriers) possibly
precluding follow-up
Sample size: 339 participants (total population), 7 participants with history of stroke
and/or TIA
Participants randomised to intervention group (only stroke and/or TIA population): 3
(analysed, not stated if more were randomised)
Participants randomised to control group (only stroke and/or TIA population): 4 (anal-
ysed, not stated if more were randomised)
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
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ESPRIT (Continued)
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Italy
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: Esapent capsules of ethyl ester ω-3 fatty acids concentrates, each containing
85% pure EPA, 50% and DHA, 35%, with 3 mg vitamin E. At a dose of 6 capsules/day
for 2 months (starting 1 month before PTCA) and subsequently reduced to 3 capsules/
day until the end of follow-up (further 5 months)
Control: identically appearing olive oil placebo capsules, with 3 mg vitamin E. Same
dose as intervention
Compliance: plasma fatty acids evaluation
Duration of intervention: 7 months
Co-interventions: either aspirin (100 to 500 mg/day) or indobufen (400 mg/day) be-
ginning at least 48 hours before PTCA. Nitrates and anticoagulation with 10,000 IU IV
heparin at the start of the PTCA procedure. Heparin administration was subsequently
adjusted with 1 or more further boluses or infusion in order to maintain the activated
clotting time at > 300 seconds and was then tapered off at least 4 hours before sheath
removal and up to 24 hours post-PTCA. After PTCA, either aspirin or indobufen for
at least 15 days. Other treatments, such as calcium antagonists, β-blockers, and nitrates
were discretionary
Outcomes Primary outcome of study: post-PTCA restenosis
Relevant review outcomes measured (in total population): vascular-related death, adverse
events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 7 months after start of intervention (6 months post-
PTCA)
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: replied, no further data available
Notes Dietary information: none provided
Funding: Pharmacia-Upjohn Italia SpA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information about random sequence
generation
Allocation concealment (selection bias) Unclear risk No details about allocation process
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind; however, no
further information provided on blinding
process
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ESPRIT (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details about how relevant review out-
comes (vascular-related death and adverse
events) were determined or assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Balanced intervention and control groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
Farquharson 2011
Methods RCT; parallel; placebo-controlled
Number of study sites: 1
Dates: study enrolment between April 2006 and December 2009
Participants Inclusion criteria: patients > 18 years of age who were accepted for cardiac surgery
involving CABG and/or valve repair or replacement
Exclusion criteria: previous diagnosis of AF or atrial flutter; antiarrhythmic drug use
(class 1 or 3) within the previous 3 months; urgent surgery (< 3 weeks); New York Heart
Association class IV heart failure; MI within previous 2 weeks; or any condition that
might affect the ability to ingest or absorb dietary fat; patients who consumed dietary
supplements rich in omega-3 oils, e.g. fish oil or flaxseed oil; or self-reported habitual
consumption of ≥ 1 fish meal per week
Sample size: 200 participants (total population), 9 participants with history of stroke
Participants randomised to intervention group (only stroke population): 5 (analysed,
not stated if more were randomised)
Participants randomised to control group (only stroke population): 4 (analysed, not
stated if more were randomised)
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Australia
Ethnicity: not stated
Interventions Comparison groups: fish oil versus control
Intervention: oil supplied in liquid form (Melrose Laboratories, Pty. Ltd., Mitcham,
Victoria, Australia), citrus flavoured. At a dose of 15 mL/day, providing EPA ~2.7 g/day
and DHA ~1.9 g/day
Control: Sunola oil supplied in liquid form (Melrose Laboratories, Pty Ltd, Mitcham,
Victoria, Australia), citrus flavoured, at a dose of 15mL/day
Compliance: fatty acid analysis in blood
Duration of intervention: up to 4 weeks, commencing 3 weeks before scheduled surgery
date until 6 days after surgery or until discharge (whichever came first)
Co-interventions: N/A
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Farquharson 2011 (Continued)
Outcomes Primary outcome of study: occurrence of sustained AF/atrial flutter (duration 10 minutes
or requiring intervention) after cardiac surgery
Relevant review outcomes measured (in total population): recurrent events (stroke),
adverse events
Available outcome data for stroke population only: none
Latest time point of assessment: up to 4 weeks after start of intervention
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: no reply up to date
Notes Dietary information: exclusion of patients who consumed dietary supplements rich in
omega-3 oils, e.g. fish oil or flaxseed oil, or self-reported habitual consumption of > 1
fish meal per week
Funding: the National Health and Medical Research Council of Australia, Canberra, Aus-
tralia; additionally, the National Heart Foundation of Australia (supporting Dr Sanders)
and the National Health and Medical Research Council of Australia (supporting Dr
Gibson)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Group assignment was based on a
computer-generated randomization list us-
ing blocks of 20”
Allocation concealment (selection bias) Unclear risk Quote: “Individual allocation was by sealed
envelope”. Not stated who prepared the en-
velopes or description of the process
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Subjects, physicians, nurses, asses-
sor and data analyst are blinded to treat-
ment allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Subjects, physicians, nurses, asses-
sor and data analyst are blinded to treat-
ment allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Small and similar amount of participants
lost after randomisation
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
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FAVOURED
Methods RCT; parallel; placebo-controlled
Number of study sites: 35
Dates: recruitment between 21 August 2008 and 28 February 2014. Last follow-up on
28 February 2015
Participants Inclusion criteria: adults (age > 19 years) with stage 4 or 5 chronic kidney disease receiving
or planned to receive haemodialysis within 12 months and scheduled for AVF surgery
in the arm
Exclusion criteria: increased bleeding risk (bleeding disorder, recent or active gastroin-
testinal ulcer, platelet count < 100 × 103/µL, hepatic insufficiency); taking aspirin within
2 weeks or fish oil within 4 weeks of trial commencement; taking nonsteroidal anti-
inflammatory drugs, anticoagulants, or antiplatelet agents; contraindications for taking
the study agents. In June 2011, the exclusion criterion of current use of aspirin was
removed so that participants currently taking aspirin were eligible for recruitment
Sample size: 567 participants (total population), 17 participants with history of stroke
Participants randomised to intervention group (only stroke population): 6
Participants randomised to control group (only stroke population): 11
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Australia, Malaysia, New Zealand, and the UK
Ethnicity: (total population information only). Fish oil group: Asian 92 (32%), White
144 (51%), Indigenous (Aboriginal, Torres Strait Islanders, Maori, and Pacific Islanders)
39 (14%), Other 9 (3%). Placebo group: Asian 89 (32%), White 154 (55%), Indigenous
(Aboriginal, Torres Strait Islanders, Maori, and Pacific Islanders) 27 (10%), Other 11
(4%)
Interventions Comparison groups: fish oil versus placebo. Participants not taking open-label aspirin
were randomised also to aspirin (100 mg) or matching placebo
Intervention: Omacor capsules, 4 g/day of omega-3 PUFAs (46% EPA and 38% DHA)
Control: 4 g/day matching placebo capsules (olive oil)
Compliance: capsule count at the week 12 visit. Centres in Australia and New Zealand
additionally tested erythrocyte fatty acids levels
Duration of intervention: 12 months
Co-interventions: 100 mg/day of oral aspirin or matching placebo (for participants not
taking open-label aspirin)
Outcomes Primary outcome of study: fistula failure, a composite of fistula thrombosis and/or aban-
donment and/or cannulation failure
Relevant review outcomes measured (in total population): adverse events
Available outcome data for stroke population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: replied, no data provided
Notes Dietary information: individuals taking fish oil within 4 weeks of trial commencement
were excluded. No further information provided
Funding: National Health and Medical Research Council of Australia Project Grant
(APP458652), Amgen Australia Pty Ltd and Mylan EPD (at the time of funding was
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FAVOURED (Continued)
Abbott Products Operations AG). Study medication supplied by Mylan EPD (at the
time of supply was Abbott Products Operations AG) (fish oil and placebo) and Bayer
Healthcare (aspirin and placebo) free of charge
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was achieved us-
ing a minimisation method to balance
treatments over two stratification factors:
study site and AVF location (upper versus
lower arm)”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed by
a central, web-based system (Flexetrials)”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants, caregivers, treating
physicians and surgeons, laboratory staff,
and members of the study team were
blinded to treatment allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk For the primary outcome assessment we
consider low risk of bias, as per the follow-
ing quote: “AVF Access Failure was assessed
independently by two observers, each un-
aware of the participant’s treatment assign-
ment, treatment course or medical history”.
However, there is no indication of who was
measuring/reporting adverse events (rele-
vant outcome for this review)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants excluded from analysis bal-
anced among groups
Selective reporting (reporting bias) Unclear risk Adverse events in the protocol appear as
secondary outcomes; however, in the results
are given in separate table, rather than with
the rest of the secondary outcomes and in
a very general manner (no supplemental
data). Tertiary outcomes (not relevant for
the review) were not fully reported
Other bias Low risk None detected
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FOILS
Methods RCT; parallel, placebo-controlled
Number of study sites: 1
Dates: randomisation from 29 July 2004 to 23 December 2005. Last follow-up in March
2006
Participants Inclusion criteria: participants were aged > 45 years, clinically stable, and with a history
of CT-confirmed first-ever or recurrent ischaemic stroke of probable noncardioembolic
aetiology > 3 months before registration
Exclusion criteria: intolerance/hypersensitivity to fish/fish oils; current use of fish oil
supplements; malabsorptive bowel diseases; or participation in a concurrent clinical trial
Sample size: 102 participants (total population, all with history of ischaemic stroke)
Participants randomised to intervention group: 51
Participants randomised to control group: 51
Sex: fish oil = 41 men and 10 women, placebo oil = 31 men and 20 women
Age, years (mean ± SD): fish oil group = 64 ± 10, placebo oil group = 65 ± 12
Time from last event (ischaemic stroke) to start of intervention (median and IQR): fish
oil group = 1.18 (0.5, 2.1) years, placebo oil group = 0.90 (0.5, 2.3) years
Type of baseline stroke: ischaemic
Country: New Zealand
Ethnicity: not stated
Interventions Comparison groups: fish oil versus placebo oil
Intervention: 3 g/day (3 × 1 g capsules) of fish oil (Hoki liver oil) supplement containing
approximately 1.2 g/day total omega-3 PUFA
Control: matching placebo (palm and soy oils), 3 g/day
Compliance: capsule count and analysis of serum phospholipid fatty acid methyl esters
Duration of intervention: 12 weeks
Co-interventions: N/A
Outcomes Primary outcome of study: change in serum triglycerides between baseline and 12 weeks
Relevant review outcomes measured: vascular-related death (due to MI), quality of life,
mood
Available outcome data for stroke and/or TIA population only: vascular-related death
(due to MI), quality of life, mood
Latest time point of assessment: 12 weeks
Withdrawals or exclusions, n (stroke and/or TIA population only): fish oil = 4 refused
follow-up, placebo oil = 2 refused follow-up, 1 death. Data missing at follow-up were
imputed using last value carried forward
Study authors’ contact status: replied, no data provided
Notes Dietary information: participants advised to abstain from other fish oil supplements,
and maintain their habitual diet
Funding: The Health Research Council of New Zealand. The Maurice and Phyllis
Paykel Trust, New Zealand (LDL particle size and fatty acid analyses). Sea Dragon, New
Zealand, provided the fish oil and Nutrition Laboratories, New Zealand, provided the
placebo treatment and encapsulated the oils
Risk of bias
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FOILS (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization was a blocked
(varying block sizes), unstratified design se-
quence.”
Allocation concealment (selection bias) Low risk Quote: “Sequential allocation of packs to
patients after confirmation of inclusion cri-
teria [...] generated using an automated In-
ternet-based system held at the Clinical Tri-
als Research Unit, University of Auckland.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Treatment packs blinded for treat-
ment”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It does not state who assessed the outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed adequately. Partici-
pants lost to follow-up distributed evenly
among groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
Foroughinia 2018
Methods RCT; parallel, open label
Number of study sites: 1
Dates: September to December 2016 (study stopped early )
Participants Inclusion criteria: ischaemic stroke confirmed via a brain CT scan, or MRI; patients
undergoing carotid stenting (more than 50% stenosis of the internal carotid artery in
symptomatic patients, or 70% stenosis in asymptomatic patients); 18 to 80 years old
Exclusion criteria: unsatisfactory carotid artery stenting; intraluminal thrombus over the
stenosis; pretreatment with glycoprotein IIb/IIIa antagonists or bivalirudin; active bleed-
ing; sensitivity or intolerance to aspirin or clopidogrel or omega-3; severe adverse effects
to drugs; percutaneous intervention; surgery less than 30 days; patients with intracranial
haemorrhage; cardio-aortic embolic strokes; lacunar infarcts; and non-atherosclerotic
causes of carotid stenosis. Additionally: patients with mRS ≥ 3; and patients who had
contraindications for angiography
Sample size: 18 participants (total population, all with history of ischaemic stroke)
Participants randomised to intervention group: 8
Participants randomised to control group: 10
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Foroughinia 2018 (Continued)
Sex: intervention = 4 men and 4 women, control = 5 men and 5 women
Age, years (mean ± SD and range): intervention = 75.2 ± 6.2, range: 65 to 82; control:
71.7 ± 6.8, range: 57 to 83
Time from event (ischaemic stroke) to start of intervention: not stated
Type of baseline stroke: ischaemic
Country: Iran
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs (EPA and DHA) versus no intervention
Intervention: 3000 mg loading dose of marine-derived n-3 PUFAs 12 hours before CAS.
Providing 990 mg EPA and 660 mg DHA (Premium V Life Company, UK). *The
abstract mentions a second dose of 1000 mg the day after the procedure (not mentioned
elsewhere)
Control: no intervention
Compliance: N/A (1-time intervention)
Duration of intervention: 1 loading dose (see above)
Co-interventions: heparin (during CAS, 80 units per kilogram of body weight); clopi-
dogrel (loading dose of 600 mg and 75 mg/day thereafter); and aspirin (loading dose of
325 mg and 80 mg/day thereafter)
Outcomes Primary outcome of study: composite outcome of any stroke, MI and/or mortality
Relevant review outcomes measured (in total population): recurrent events (ischaemic
stroke); incidence of other type of stroke (haemorrhagic stroke); adverse events
Available outcome data for stroke and/or TIA population only: recurrent events (is-
chaemic stroke); incidence of other type of stroke (haemorrhagic stroke); adverse events
Latest time point of assessment: 30 days after procedure (planned), actual time not stated
Withdrawals or exclusions, n: none (study stopped)
Study authors’ contact status: no reply to date
Notes Dietary information: none provided
Funding: Office of Vice Chancellor for Research in Shiraz University of Medical Sciences,
Shiraz, Iran
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Unclear risk They report that the statistician was
blinded but they did not specify who allo-
cated the participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Only analysts are blinded in this
study”
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Only analysts are blinded in this
study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data provided for all the participants en-
rolled up to early termination of study
Selective reporting (reporting bias) Unclear risk Death and MI not reported, unclear if there
were no cases or if data are missing
Other bias Low risk None detected
FORωARD
Methods RCT; parallel, placebo-controlled.
Number of study sites: 42
Dates: recruitment from January 2008 to March 2011. Last follow-up on February 2012
Participants Inclusion criteria: patients must have either (1) at least 2 symptomatic episodes of doc-
umented AF in the previous 6 months before randomisation, with the last episode oc-
curring in the 14 to 90 days before randomisation (paroxysmal AF), or (2) successful
electrical or pharmacologic cardioversion for persistent AF performed in the 14 to 28
days before randomisation. All participants < 65 years of age must present with at least
1 of the following characteristics of moderate-to-high risk of stroke: heart failure (New
York Heart Association (NYHA) I to III) or documented ejection fraction < 40%, type
II diabetes mellitus, coronary artery disease, peripheral vascular disease, hypertension,
previous TIA or stroke
Exclusion criteria: contraindications for use n-3 PUFA; heart failure in NYHA class IV;
acute coronary syndromes, coronary artery bypass surgery, or valve replacement within
the past 3 months; clinically significant valvular disease; known diagnosis of Wolff-
Parkinson-White; planned or recent (< 6 months) implantation of pacemaker and/or
implantable cardio-defibrillator; planned or recent (< 6 months) ablative treatment for
AF; any arrhythmia associated with an acute reversible condition (thyroid dysfunction,
hypoxia, anaemia, others); advanced chronic lung disease and pregnancy or lactation
Sample size: 586 participants (total population), 27 participants with history of stroke
Participants randomised to intervention group (only stroke population): 14
Participants randomised to control group (only stroke population): 13
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke to start of intervention: not stated
Type of baseline stroke: not stated
Country: Argentina
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: capsules containing 1 g/day of marine-derived n-3 PUFAs (850 to 882 mg
EpA/DHA ethyl esters)
Control: 1 g/day of olive oil (matching odour and fishy aftertaste)
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Compliance: method not described, only time points (2, 4, 8 and 12 months after
randomisation)
Duration of intervention: 12 months
Co-interventions: treatment prescribed for AF (anticoagulants, antiplatelet agents, an-
tiarrhythmics (amiodarone or others), β-blockers, calcium-channel blockers, or other
therapies as needed)
Outcomes Primary outcome of study: time to first recurrence of an AF episode of symptomatic or
asymptomatic AF (documented by a 12-lead electrocardiogram)
Relevant review outcomes measured (in total population): stroke, adverse events
Available outcome data for stroke population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: quote “It should be acknowledged as a limitation that we did not
track fish consumption among participants. It could be that high fish intake might have
mitigated the effect of oral supplementation. Although this is possible, it should also be
noted that fish intake is low-to-very-low in Argentina”
Funding: SPA and Sigma Tau
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on random sequence generation
Allocation concealment (selection bias) Low risk Quote: “participants are centrally assigned .
.. each study site will be supplied with study
drug and placebo in identically appearing
packaging”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients, investigator staff, persons
performing the assessments, and data ana-
lysts will remain blind to the identity of the
treatment from the time of randomization
until database lock”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, investigator staff, persons
performing the assessments, and data ana-
lysts will remain blind to the identity of the
treatment from the time of randomization
until database lock”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Fewer participants randomised to interven-
tion group
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Selective reporting (reporting bias) Low risk Rationale published before randomisation
finished, all outcomes reported
Other bias Unclear risk Trial stopped before reaching number of
volunteers originally sought
Gammelmark 2012
Methods RCT; parallel; placebo-controlled
Number of study sites: 1
Dates: between April and December 2009
Participants Inclusion criteria: participants (age 30 to 75 years) with a waist circumference of more
than 80 cm in women or more than 94 cm in men, according to the World Health
Organization definition of abdominal obesity in a European population. Women had to
be postmenopausal and not receiving hormone replacement therapy
Exclusion criteria: taking anti-inflammatory drugs other than low-dose acetylsalicylic
acid; chronic or acute inflammatory condition; dysregulated DM (HbA1c > 8%); ma-
lignant disease; chronic alcoholism; or severe renal insufficiency (glomerular filtration
rate < 30 mL/min). People taking fish oil supplements before inclusion were required to
stop the supplements for at least 12 weeks before inclusion
Sample size: 50 participants (total population), 4 participants with history of stroke
Participants randomised to intervention group (only stroke population): 2
Participants randomised to control group (only stroke population): 2
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Denmark
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: 2 g/day of fish oil (640 mg of EPA and 480 mg of DHA)
Control: 2 g/day of olive oil (similarity to intervention not stated)
Compliance: fatty acid composition assessed (granulocytes and adipose tissue)
Duration of intervention: 6 weeks
Co-interventions: N/A
Outcomes Primary outcome of study: inflammatory markers
Relevant review outcomes measured (in total population): adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 6 weeks
Withdrawals or exclusions, n (stroke and/or TIA population only): not stated
Study authors’ contact status: no reply to date
Notes Dietary information: the frequency and amount of fish intake (fatty and lean fish) were
reported at baseline. Daily intake of n-3 PUFAs was calculated using tabulated values.
Participants advised to maintain their regular diet throughout the study
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Funding: Spar Nord Foundation, the Obelske Family Foundation and Heinrich Kopp’s
Grant. Capsules supplied by Napro Pharma, Brattvaag, Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details about random sequence genera-
tion provided
Allocation concealment (selection bias) Unclear risk No information about allocation process
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as “double blind”;
however, no details provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessment of adverse events not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants balanced across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk It is not stated if the participant that
dropped out was included in the analysis.
Tables of outcomes do not indicate sample
size
GISSI HF
Methods RCT; parallel; placebo-controlled
Number of study sites: 357
Dates: randomisation between 6 August 2002 and 28 February 2005. Follow-up con-
cluded on 31 March 2008
Participants Inclusion criteria: men and women aged 18 years or older, with clinical evidence of heart
failure of any cause that was classified according to the European Society of Cardiology
guidelines as New York Heart Association (NYHA) class II-IV, provided that they had
had their LVEF measured within 3 months before enrolment. When LVEF was greater
than 40%, the patient had to have been admitted at least once to hospital for heart failure
in the preceding year to meet the inclusion criteria
Exclusion criteria: specific indication or contraindication to n-3 PUFA; known hyper-
sensitivity to study treatments; presence of any non-cardiac comorbidity (e.g. cancer)
that was unlikely to be compatible with a sufficiently long follow-up; treatment with any
investigational agent within 1 month before randomisation; acute coronary syndrome
or revascularisation procedure within the preceding 1 month; planned cardiac surgery,
expected to be done within 3 months after randomisation; significant liver disease; and
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pregnant or lactating women or women of childbearing potential who were not ade-
quately protected against becoming pregnant; conditions that in the opinion of the in-
vestigator would be associated with poor adherence to the protocol; background therapy
including: (1) for randomisation to n-3 PUFA, an ongoing post-MI treatment with n-
3 PUFA; (2) for randomisation to rosuvastatin, lipid-lowering therapy with statins
Sample size: 6975 participants (total population), 346 participants with history of stroke
Participants randomised to intervention group (only stroke population): 168
Participants randomised to control group (only stroke population): 178
Sex (only stroke population): marine-derived n-3 PUFAs group = 130 men and 38
women; placebo = 145 men and 33 women
Age, years (only stroke population) mean ± SD: marine-derived n-3 PUFAs group = 71
± 8; placebo = 70 ± 9
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Italy
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo. Participants without
specific indications or contraindications to statins were further randomised to rosuvas-
tatin or corresponding placebo
Intervention: 1 capsule per day of 1 g marine-derived n-3 PUFAs (850 to 882 mg EPA
and DHA as ethyl esters in the average ratio of 1:1.2)
Control: matching placebo (no further details)
Compliance: a participant was regarded as compliant to the treatment if the study drug
was administered for at least 80% of the days of observation
Duration of intervention: median of 3.9 years (IQR 3.0 to 4.5)
Co-interventions: participants also randomised to rosuvastatin (10 mg/day) or corre-
sponding placebo
Outcomes Primary outcome of study: time to death, and time to death or admission to hospital for
cardiovascular reasons
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events; adverse events
Available outcome data for stroke population only: vascular-related death; recurrent
events (stroke)
Latest time point of assessment: median of 3.9 years (IQR 3.0 to 4.5)
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: replied, data provided
Notes Dietary information: treatment with n-3 PUFA was part of exclusion criteria. Further
data not provided for overall study; however, in a sub-study (51 centres) authors report
the following (quote): “fish consumption was distributed between never consumers (25.
6%), those consuming fish about once per week (36.3%), and those consuming fish 2
or more times per week (38.1%). Baseline levels of n-3 PUFA were positively associated
with the frequency of fish consumption [...] There was no specific information on the
consumption of types of fish such as oily fish, which have highest levels of EPA and
DHA”
Funding: pool of financial grants by the companies which are the owners and the suppliers
of the study drugs (Pharmacia-Upjohn, Sigma-Tau, and Societa’ Prodotti Antibiotici
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supply capsules containing 850 to 882 mg EPA/DHA ethyl esters; rosuvastatin is supplied
by Astra-Zeneca)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computerised telephone random-
ization system”
Allocation concealment (selection bias) Low risk Quote: “Allocation of patients to treatment
groups will be accomplished via a telephone
call-in system, and centrally approved at the
study Coordinating Centre”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All patients and study personnel
were blinded to treatment”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All the events recorded in the study
were adjudicated blindly by an ad-hoc com-
mittee on the basis of pre-agreed definitions
and procedures”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants discontinuing study treatment
balanced across intervention and control
groups
Selective reporting (reporting bias) Low risk Rationale published before randomisation
period finished. All pre-specified outcomes
were reported
Other bias Low risk None detected
Green 1985
Methods RCT; cross-over; placebo-controlled
Number of study sites: 1
Dates: not stated
Participants Inclusion criteria: patients with completed stroke or TIAs
Exclusion criteria: not stated
Sample size: 18 participants (total population, all with history of ischaemic stroke or
TIA) with 7 drop outs, all data provided only for the participants that completed the
trial (n = 11)
Participants randomised to intervention group: 4 on the first period, 7 on the second
one
Participants randomised to control group: 7 on the first period, 4 on the second one
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Sex: 7 men, 4 women
Age: range from 53 to 76 years
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: ischaemic
Country: USA
Ethnicity: not stated
Interventions Comparison groups: MaxEPA versus placebo
Intervention: 10 capsules were given daily in divided doses, 180 mg of EPA per capsule
(10 mL of MaxEpa daily, i.e. 1.8 g/day of EPA)
Control: 10 capsules of olive oil given daily
Compliance: not stated
Duration of intervention: 6 weeks
Co-interventions: vitamin E, 100 mg per 100 g (added to each oil to prevent oxidation)
Outcomes Primary outcome of study: effects on cholesterol, triglycerides, and platelet function
Relevant review outcomes measured (in total population): adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 6 weeks (cross-over design: therefore 12 weeks of par-
ticipation in total)
Withdrawals or exclusions, n (stroke and/or TIA population only): 7
Study authors’ contact status: replied, no further data available
Notes Dietary information: participants remained on the diets prescribed by their attending
physicians, and no changes occurred during the course of the study
Funding: Seven Seas Health Care Limited provided the study medications
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A table of random numbers was
kept by the pharmacy”
Allocation concealment (selection bias) Unclear risk Quote: “The pharmacists dispensed either
study medication or placebo based on this
table”. No information about allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The medications were packaged in
opaque capsules”. Intervention dispensed
by pharmacist
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not specified who is assessing outcomes
or the stage at what the code was broken
Incomplete outcome data (attrition bias)
All outcomes
High risk High rate of dropouts (data not imputed)
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Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
JELIS
Methods RCT; parallel, open label, blinded end point
Number of study sites: multicentre study, number of sites not stated
Dates: enrolment between November 1996 and November 1999. Last follow-up Novem-
ber 2004
Participants Inclusion criteria: serum total cholesterol of 250 mg/dL or more; if taking antihyperlipi-
daemic drugs for more than 6 months, washout period of 4 weeks (8 weeks for probucol)
; men aged 40 to 75 years or women after menopause to 75 years; patients who have
already received appropriate dietary advice
Exclusion criteria: acute MI occurring within last 6 months; unstable angina pectoris;
history or complication of serious heart disease (severe arrhythmia, heart failure, cardiac
myopathy, valvular disease, congenital disease, etc.); receiving cardiovascular reconstruc-
tion within last 6 months; cerebrovascular disorders occurring within last 6 months;
complication of serious hepatic disease or renal disease; malignant tumour; uncontrol-
lable diabetes; hyperlipidaemia arising from the following diseases: nephrotic syndrome,
hypothyroidism, Cushing’s syndrome, secondary hyperlipidaemia due to other disease;
hyperlipidaemia due to some drugs such as steroid hormone; haemorrhage (haemophilia,
capillary fragility, gastrointestinal ulcer, urinary tract haemorrhage, haemoptysis, vitre-
ous haemorrhage, etc.); haemorrhagic diathesis; hypersensitivity to the study drug for-
mulation; patients intending to undergo surgery; patients judged to be inappropriate by
the physician in charge
Sample size: 18,645 participants (total population), 942 participants with history of
stroke or TIA
Participants randomised to intervention group (only stroke or TIA population): 485
(analysed, not stated if more were randomised)
Participants randomised to control group (only stroke or TIA population): 457 (analysed,
not stated if more were randomised)
Sex (only stroke or TIA population): no EPA group = 180 men and 277 women, EPA
group = 189 men and 296 women
Age, years (only stroke or TIA population) mean ± SD: no EPA group = 65 ± 7, EPA
group = 66 ± 7
Time from event (stroke or TIA) to start of intervention: not stated, at least 6 months
(as per exclusion criteria)
Type of baseline stroke: both ischaemic and haemorrhagic (cerebral thrombosis n = 467;
cerebral embolism n = 150; TIA n = 86; cerebral haemorrhage n = 80; subarachnoid
haemorrhage n = 38; unknown n = 121)
Country: Japan
Ethnicity: Japanese
Interventions Comparison groups: EPA versus no EPA
Intervention: EPADEL capsules containing 300 mg of highly (> 98%) purified EPA
ethyl ester per capsule. Total daily dose of 1800 mg
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Control: no intervention (open label)
Compliance: process not described. Quote: “Local physicians monitored compliance [..
.] at every clinic visit”
Duration of intervention: maximum of 5 years
Co-interventions: either pravastatin (10 to 20 mg/day); or simvastatin (5 to 10 mg/day)
Outcomes Primary outcome of study: major coronary events
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events; adverse events
Available outcome data for stroke and/or TIA population only: recurrent events
Latest time point of assessment: mean 4.6 years (SD 1.1)
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: participants received “appropriate” dietary advice, no details pro-
vided
Funding: Mochida Pharmaceutical Co Ltd, Tokyo, Japan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We used a permuted block ran-
domization with a block size of 4. Multiple
blocks were assigned according to the num-
ber of participants enrolled at each centre.
Stratification was based on the prevention
stratum (primary or secondary).”
Allocation concealment (selection bias) Low risk Quote: “The results of the randomization
scheme were concealed to the investigators
and participants”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Clinical end points are ascertained
once a year by the Endpoints Adjudication
Committee: expert cardiologists and neu-
rologists who are blinded to the assigned
groups. However, the assessment of the end
points is performed without breaking a key
code, by a blinded-end point approach.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In total population (no only stroke sub-
sample), considerably more participants
withdrew consent in intervention group.
Insufficient information about discrepancy
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reasons and stroke population specifically
Selective reporting (reporting bias) Unclear risk No protocol available. Rationale published
after randomisation period finished
Other bias Low risk None detected
Nosaka 2017
Methods RCT; parallel; open label.
Number of study sites: 1
Dates: recruiting between November 2010 and March 2014
Note: 115 participants from this study overlapped with another included trial (Doi 2014)
; however, none of them are contributing data to the review
Participants Inclusion criteria: acute coronary syndrome patients treated with percutaneous coronary
intervention
Exclusion criteria: cardiogenic shock; severe renal insufficiency requiring dialysis; car-
diopulmonary arrest; emergent coronary artery bypass; failure of PCI; and expected
prognosis less than 1 year because of cancer
Sample size: 241 participants (total population), 23 participants with history of stroke
Participants randomised to intervention group (only stroke population): 8 (analysed,
not stated if more were randomised)
Participants randomised to control group (only stroke population): 15
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Japan
Ethnicity: not stated
Interventions Comparison groups: EPA versus no EPA
Intervention: highly (> 98%) purified EPA ethyl ester (ethyl all cis-5,8,11,14,17-icos-
apentaenoate), at a dose of 1800 mg
Control: no placebo
Compliance: not stated
Duration of intervention: at least 52 weeks
Co-interventions: pitavastatin 2 mg/day started within 24 hours after PCI for at least 52
weeks
Outcomes Primary outcome of study: cardiovascular events after acute coronary syndrome
Relevant review outcomes measured (in total population): vascular-related death, recur-
rent events, adverse events
Available outcome data for stroke population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: no reply to date
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Notes Dietary information: not provided
Funding: Mochida Pharmaceutical Co, Ltd (speaker honoraria)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “According to a computer-gen-
erated randomization plan that included
stratification by gender and acute MI or
unstable angina pectoris”
Allocation concealment (selection bias) Unclear risk Unclear if allocation was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Diagnoses were confirmed by an
investigator (M.I.), who was blind to treat-
ment allocation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Small and similar amount of participants
lost after randomisation
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
NUTRISTROKE
Methods RCT; parallel; 2 × 2 factorial design
Number of study sites: 1
Dates: between June 2004 and February 2006
Participants Inclusion criteria: first ischaemic stroke survivors admitted to rehabilitation unit
Exclusion criteria: onset-admission interval > 60 days; haemorrhagic lesions and the
presence of other chronic disabling pathologies and/or medical conditions that would
contraindicate physical therapy; and inability or refusal to give consent
Sample size: 72 participants (total population, all with history of stroke)
Participants randomised to intervention group: 38 (marine-derived n-3 PUFAs and
antioxidants + marine-derived n-3 PUFAs groups)
Participants randomised to control group: 34 (antioxidants and placebo groups)
Sex: antioxidants = 8 men and 8 women; marine-derived n-3 PUFAs = 15 men and 5
women; antioxidants + marine-derived n-3 PUFAs = 13 men and 5 women; placebo =
11 men and 7 women
Age, years (article does not indicate if the variance is SD): antioxidants = 65.1 ± 12.8,
marine-derived n-3 PUFAs = 61.3 ± 13.6, antioxidants + marine-derived n-3 PUFAs =
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66.3 ± 11.4, placebo = 68.4 ± 12.6
Time from event (stroke) to start of intervention: less than 60 days (as per exclusion
criteria)
Type of baseline stroke: ischaemic
Country: Italy
Ethnicity: not stated
Interventions Comparison groups: 4 groups: marine-derived n-3 PUFAs; marine-derived n-3 PUFAs
+ antioxidants; antioxidants; and placebo. This review collated the groups in 2: marine-
derived n-3 PUFAs (including marine-derived n-3 PUFAs, and marine-derived n-3 PU-
FAs + antioxidants) versus no marine-derived n-3 PUFAs (antioxidants, and placebo)
Intervention: gelatin capsules from fish oil, 500 mg n-3 PUFAs (250 mg DHA and 250
mg EPA) daily with or without antioxidants (290 mg vitamin E, 240 mg vitamin C, 150
mg polyphenols and 19 mg β-carotene)
Control: placebo did not include polyunsaturated fatty acids; however, composition is
not detailed
Compliance: investigated every month by meetings or telephone interview with the
participant, no further details
Duration of intervention: 12 months
Co-interventions: participants were also randomised to receive antioxidants or placebo
(see above)
Outcomes Primary outcome of study: functional status in post-stroke rehabilitation
Relevant review outcomes measured (in total population): efficacy (measured by Barthel
Index); vascular-related death
Available outcome data for stroke and/or TIA population only: efficacy (measured by
Barthel Index); vascular-related death
Latest time point of assessment: 12 months
Withdrawals or exclusions, n: 20 dropouts (including 4 deaths for cardiovascular events)
Study authors’ contact status: no reply to date
Notes Dietary information: standardised diet for all participants. The nutritional characteristics
of the standard diet were established to guarantee restoration and preservation of an
optimal nutritional state and to meet energy and nutrient requirements. Specific meals
were utilised during the hospitalised rehabilitation period and after the hospital discharge
to continue the trial at home (menu Nutristroke). Fulfilment of nutritional needs was
reached by increasing the amount of nutrients up to 125% of daily need and providing
food of high nutritional density; as is usual in medical facilities, consumption of food
is up to 75% of that provided. The meals proposed favoured foods rich in antioxidants
and n-3 fatty acids. To verify compliance with the dietetic programme a precise weighing
method was used, consisting of 5 surveys over the trial period (2 in the hospital and
3 at home), and each survey lasted a week. During hospitalisation, dietitians weighed
and recorded all the food offered to participants before eating and leftovers after eating.
Before discharge, participants or their caregivers were trained about the diet and the
method of surveying discarded food
Funding: Italian Ministry of Health (grant No. RF02.216-BS4B.5.4). Sigma-Tau Health
Science, Rome provide n-3 supplements
Risk of bias
62Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NUTRISTROKE (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Enrolled patients were random-
ized, by means of a specific list”. No infor-
mation on how the list was generated
Allocation concealment (selection bias) Unclear risk No details about allocation process
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “No patient, research assistant, in-
vestigator or any other medical or nursing
staff could distinguish the placebo from the
supplements during the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The code was broken only after
data recording had been completed”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Small study size with big differences in
numbers of people lost during follow-up
between groups (attenuated after removing
deaths)
Selective reporting (reporting bias) Unclear risk Neurological impairment outcome (not
relevant for this review) measured by Cana-
dian Neurological Scale was not reported
by intervention group
Other bias Unclear risk Quote: “No side effects were registered”. It
does not explain if they were interrogated
or not
OCEAN
Methods RCT; parallel; placebo-controlled
Number of study sites: 2
Dates: recruitment from March 2003 to December 2004
Participants Inclusion criteria: awaiting carotid endarterectomy; > 18 years of age; and ability to give
written informed consent
Exclusion criteria: regular consumption of more than 2 oily fish meals per week; use of fish
oil or evening primrose oil supplements; being pregnant or breast feeding; participation
in another clinical trial; or requiring surgery within 7 days
Sample size: 121 participants (total population), data provided only for participants who
completed the trial (n = 100), 85 participants with history of stroke and/or TIA (both
within 6 months and more than 6 months prior to start of intervention, not clear if
duplicates included)
Participants randomised to intervention group (only stroke and/or TIA population):
38 (only participants who completed the trial, both within 6 months and more than 6
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months prior to start of intervention, not clear if duplicates included)
Participants randomised to control group (only stroke and/or TIA population): 47 (only
participants who completed the trial, both within 6 months and more than 6 months
prior to start of intervention, not clear if duplicates included)
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: UK
Ethnicity: not stated
Interventions Comparison groups: Marine-derived n-3 PUFAs ethyl esters versus placebo
Intervention: Omacor capsules (approximately 888 mg EPA and 777 mg DHA per day)
Control: olive oil capsules (providing 1.55 g of oleic acid per day)
Compliance: returned capsules count
Duration of intervention: median 21 days (range: 7 to 102 days)
Co-interventions: N/A
Outcomes Primary outcome of study: atherosclerotic plaque inflammation and stability
Relevant review outcomes measured (in total population): none available
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: median 21 days (range: 7 to 102 days)
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: replied, no data provided
Notes Dietary information: exclusion of people with a regular consumption of more than 2 oily
fish meals per week, as well as those using fish oil or evening primrose oil supplements.
Participants were advised not to change their diet throughout the study
Funding: study authors supported by grants from Pronova BioPharma AS and British
Heart Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation of patients to
treatment group was according to a ran-
dom number table and was performed by
PronovaBioPharma”
Allocation concealment (selection bias) Low risk Quote: “All researchers were blind to treat-
ment allocation. Capsules were provided in
sealed containers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All researchers were blind to treat-
ment allocation”
Quote: “Capsules were identical in appear-
ance”
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Note: none of the study outcomes available
is relevant for the review, no information
about relevant outcomes detection
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Baseline information and outcome data
provided only of participants who com-
pleted the trial. Slightly higher dropout rate
in intervention group (no data imputed)
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
OMEGA
Methods RCT; parallel, placebo-controlled
Number of study sites: 104
Dates: recruitment between October 2003 and June 2007, 1 year of follow-up
Participants Inclusion criteria: male and female patients with a minimum age of 18 years; admitted
to hospital for acute ST-elevation or non-ST-elevation MI; written informed consent to
participate in the study. 75% of the included patients should have one or more of the
following risk factors: age > 70 years, ejection fraction < 40%, diabetes or no reperfusion
therapy
Exclusion criteria: pre-menopausal woman, who were pregnant, nursing or not practis-
ing birth control, and women who did not agree pregnancy testing before participating
in the study; known hypersensitivity to any component of the study drugs; patients with
haemorrhagic diathesis; patients not willing to discontinue other medications contain-
ing fish oil; known or suspected non-compliance; legal incapacity and/or other circum-
stances rendering the patient unable to understand the study; refusal or withdrawal of
the informed consent; history of drug or alcohol abuse within 6 months; any investiga-
tional therapy within 1 month of signing the informed consent; and any other clinical
condition which would not allow safe completion of the protocol and administration of
the study drugs
Sample size: 3851 participants (total population), 209 participants with history of stroke
Participants randomised to intervention group (only stroke population): 112 (intention-
to-treat population)
Participants randomised to control group (only stroke population): 97 (intention-to-
treat population)
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Germany
Ethnicity: not stated
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Interventions Comparison groups: marine-derived n-3 PUFAs ethyl esters versus placebo
Intervention: 1 g/day of marine-derived n-3 PUFAs ethyl esters (460 mg of EPA and
380 mg of DHA)
Control: 1 g/day of olive oil
Compliance: ’returned capsules’ count and blood concentrations of DHA and EPA at
the end of the study
Duration of intervention: 12 months
Co-interventions: guideline-adjusted acute and chronic medication, reperfusion therapy
(thrombolysis and/or PCI), concomitant hospital care, rehabilitation, bypass surgery or
PCI during follow-up if indicated, and lifestyle changes and risk factor management
Outcomes Primary outcome of study: rate of sudden cardiac death in participants who survived
acute MI
Relevant review outcomes measured (in total population): vascular-related death, recur-
rent events, adverse events, mood (depression, data not provided)
Available outcome data for stroke population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: assessment of the individual fish consumption based on self-reports
at the beginning of the study, at visit 2, and at the end of the study. Categories: no fish,
occasionally, several times a week, daily
Funding: Trommsdorff GmbH & Co. KG Arzneimittel, Alsdorf, Germany and Pronova
Biocare, Lysaker, Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization code for se-
quential treatment has been generated by
allphamed PHARBIL, G ttingen, Ger-
many”
Allocation concealment (selection bias) Low risk Quote: “Every container was labelled with
a 4-digit number that concealed the actual
treatment and was documented by the in-
vestigator on the patient’s case report form.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The appearance of the drugs or the
drug containers did not allow patients and
physicians to deduce the study arm.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The randomization code remains
unavailable for all investigators and all
members of the clinical project team in-
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cluding the trial monitors and the steering
committee throughout the whole study.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up balanced across groups
Selective reporting (reporting bias) High risk Depression, non-fatal resuscitation and re-
hospitalisation not reported
Other bias Low risk None detected
OMEGA PCI
Methods RCT; parallel; placebo-controlled
Number of study sites: 1
Dates: not stated
Participants Inclusion criteria: consecutive patients with stable coronary artery disease (age range 30
to 80 years) undergoing PCI with stent implantation
Exclusion criteria: acute coronary syndrome; bleeding; concomitant chronic anticoagu-
lant therapy; thienopyridine use before enrolment; platelet count < 100 x 10 /L; serum
creatinine > 177 µmol/L (2 mg/dL); and liver injury (alanine transaminase level > 1.5
times above the upper limit of the reference range)
Sample size: 63 participants (total population), 19 participants with history of stroke or
PAD (not reported separately)
Participants randomised to intervention group (only stroke population): not stated
Participants randomised to control group (only stroke population): not stated
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Poland
Ethnicity: not stated
Interventions Comparison groups: Omacor versus placebo
Intervention: 1 g/day of marine-derived n-3 PUFAs ethyl esters (Omacor, 460 mg of
EPA and 380 mg of DHA)
Control: soybean oil capsules (no further details)
Compliance: ’returned tablets’ count
Duration of intervention: 4 weeks
Co-interventions: clopidogrel, 600 mg loading dose (12 hours before PCI), then, 75
mg/day. Aspirin 75 mg/day
Outcomes Primary outcome of study: platelet responsiveness to dual antiplatelet therapy
Relevant review outcomes measured (in total population): vascular-related death, adverse
events
Available outcome data for stroke population only: none
Latest time point of assessment: 4 weeks
Withdrawals or exclusions, n (stroke population only): not available
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Study authors’ contact status: no reply to date
Notes Dietary information: baseline fish consumption was similar in both groups. Participants
were asked to comply with a diet recommended by European Society of Cardiology that
encouraged increased consumption of oily fish
Funding: The Ministry of Science and Higher Education of Poland (N402 095 31/
2947 to G.G.) and the Foundation “Helping the Heart” at the Department of Coronary
Disease, Jagiellonian University School of Medicine (SKC1 to Dr Gajos)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were then randomized in
the 1:1 ratio using computerized random-
number generation ”
Allocation concealment (selection bias) Low risk Allocation performed by an independent
investigator on a double-blind basis
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clearly stated if assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants balanced across intervention
and control groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
OPACH
Methods RCT; parallel; placebo-controlled
Number of study sites: 11
Dates: enrolment between November 2002 and May 2003. Median follow-up of 558
days
Participants Inclusion criteria: established CVD (defined as previously documented MI, angina pec-
toris, angiographically documented coronary atherosclerosis, stroke, TIA, or PAD) and
treatment with stable haemodialysis for at least 6 months
Exclusion criteria: participation in other clinical trials; active malignant disease; and
known poor compliance
Sample size: 206 participants (total population), 85 participants with history of stroke
68Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
OPACH (Continued)
and/or TIA
Participants randomised to intervention group (only stroke and/or TIA population): 41
Participants randomised to control group (only stroke and/or TIA population): 44
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Denmark
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: Omacor (marine-derived n-3 PUFAs ethyl esters). 1.7 g/day of n-3 PUFAs
Control: olive oil (2 capsules per day, containing 77% oleic acid)
Compliance: serum phospholipid fatty acid composition
Duration of intervention: 2 years or until reaching a study primary endpoint (median
of 558 days, range 219 to 730 days)
Co-interventions: N/A
Outcomes Primary outcome of study: a composite of acute MI, angina pectoris that required coro-
nary investigation or intervention, stroke, TIA, peripheral vascular disease that required
surgical intervention, or death
Relevant review outcomes measured (in total population): vascular-related death, recur-
rent events (stroke/TIA), and adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: median 558 days (range 219 to 730 days)
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: participants evaluated their habitual intake of fish at lunch and
dinner and were scored 1 to 6 points for each meal, with 1 point = “never eating fish”; 2
points = “eating fish once a month”; 3 points = “eating fish 2-3 times a month”; 4 points
= “eating fish once a week”; 5 points = “eating fish 2-3 times a week”; and 6 points =
“eating fish at least once daily”. For further analysis, the score for each meal was summed,
and patients were divided into 3 groups according to a low fish intake (scores 2 to 5), a
moderate fish intake (scores 6 to 8), and a high fish intake (scores 9 to 12)
Funding: The Danish Heart Foundation, The Danish Kidney Foundation, the Research
Foundation of the County of Northern Jutland, and Pronova Biocare
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed us-
ing an allocation sequence that was gener-
ated by computer at an independent firm,
GM pack (Hadsund, Denmark), who also
packed and delivered the capsules”
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Allocation concealment (selection bias) Unclear risk Quote: “The allocation sequence was kept
at GM pack”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All participants, investigators, care
providers, and data monitors were blinded,
according to treatment, throughout the
study. The investigators did not have ac-
cess to the allocation sequence until the
database was closed in September 2005”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “A clinical end point committee,
whose members were blinded to treatment,
evaluated all end points”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals similar across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
OPAL
Methods RCT; parallel; placebo-controlled
Number of study sites: 20
Dates: randomisation between April 2005 and March 2006, 24 months follow-up
Participants Inclusion criteria: healthy, cognitively-normal adults aged 70 to 79 years
Exclusion criteria: individuals currently diagnosed with either diabetes (Type I or Type
II) or dementia;
individuals not deemed suitable to take part in the study (e.g. recent bereavement,
terminal illness) were excluded at the discretion of general practitioner at site; current
daily use of fish-oil supplements; participants with an MMSE score of less than 24 (out
of a maximum of 30)
Sample size: 867 participants (total population), 19 participants with history of stroke
Participants randomised to intervention group (only stroke population): 10
Participants randomised to control group (only stroke population): 9
Sex (only stroke population): intervention group = 6 men and 4 women, control group
= 4 men and 5 women
Age, years ± SD (only stroke population): intervention group = 75.16 ± 2.65, control
group = 75.04 ± 3.17
Time from event (stroke) to start of intervention: not stated
Type of baseline stroke: not stated
Country: UK
Ethnicity: not stated
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Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: 700 mg/day of marine-derived n-3 PUFAs ethyl esters (200 mg of EPA
and 500 mg of DHA)
Control: olive oil (capsules)
Compliance: count of capsules, and serum fatty acid concentrations (ethical approval
obtained on May 2007)
Duration of intervention: 24 months
Co-interventions: N/A
Outcomes Primary outcome of study: cognitive function
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events; adverse events; mood (psychological health assessed by general health ques-
tionnaire)
Available outcome data for stroke and/or TIA population only: vascular-related death;
recurrent events; mood (psychological health assessed by General Health Questionnaire)
Latest time point of assessment: 24 months
Withdrawals or exclusions, n (stroke population only): intervention group = 1, control
group = 4
Study authors’ contact status: replied, data provided
Notes Dietary information: habitual fish consumption information was collected at baseline.
Categories: once a month or less; once a week/fortnight, mainly white; more than once a
week, mainly white; once a week/fortnight, mainly oily; more than once a week, mainly
oily
Funding: UK Food Standards Agency (NO5053) and the UK National Health Service
Research and Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Research nurses telephoned a cen-
tral computerized randomization service
to obtain treatment-allocation codes previ-
ously generated by the trial statistician”
Allocation concealment (selection bias) Low risk Quote: “Supplements were packaged into
identical pots, each containing 180 cap-
sules, and labelled by staff who were not
involved in the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Supplements were packaged into
identical pots, each containing 180 cap-
sules, and labelled by staff who were not
involved in the study”
Blinding of outcome assessment (detection
bias)
Low risk Quote: “All project staff were unaware of
group assignments until the completion of
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All outcomes the trial and after data analysis.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants withdrawing from study bal-
anced across intervention and control
groups
Selective reporting (reporting bias) High risk Some data not shown (psychological
health, secondary outcome) in original
publication, provided when requested to
authors
Other bias Low risk None detected
Rantanen 2018
Methods Design: RCT; parallel; placebo-controlled
Number of study sites: 3
Dates: between June 2014 and March 2016
Participants Inclusion criteria: dialysis treatment for > 3 months and age > 18 years
Exclusion criteria: pregnancy; expected life expectancy < 3 months; inability to give
informed consent; known allergy to contents of the supplemental capsules; and expected
inability to comply with study protocol
Sample size: 112 participants (total population), 31 participants with history of stroke
and/or TIA
Participants randomised to intervention group (only stroke/TIA population): 18
Participants randomised to control group (only stroke/TIA population): 13
Sex (only stroke/TIA population): not stated
Age (only stroke/TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: ischaemic, haemorrhagic and/or TIA
Country: Denmark
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: 2 g/day of marine-derived n-3 PUFAs (1 g of EPA and 1 g of DHA)
Control: olive oil (capsules)
Compliance: count of capsules, and n-3 PUFA content in plasma phospholipids
Duration of intervention: 3 months
Co-interventions: N/A
Outcomes Primary outcome of study: effect on heart rate variability
Relevant review outcomes measured (in total population): adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 3 months
Withdrawals or exclusions, n (stroke/TIA population only): not available
Study authors’ contact status: no reply to date
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Notes Dietary information: fish consumption, evaluated by a questionnaire, was similar at
baseline and did not change during the study period
Funding: The Danish Council for Strategic Research-(AF Study Group), The Arvid Nils-
son Foundation, The Danish Kidney Association, The Danish Society of Nephrology,
and Medical Specialist Heinrich Kopp’s Grant Supplement provided free of charge by
Pharma Marine, Norway
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A computer-generated permuted
block randomization determined the allo-
cation sequence”
Allocation concealment (selection bias) Unclear risk No details about process of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients, investigators and study
personal were blinded to the allocation un-
til the trial and all the analyses were com-
pleted”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, investigators and study
personal were blinded to the allocation un-
til the trial and all the analyses were com-
pleted”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar amount of dropouts in both groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
Risk & Prevention Study
Methods RCT; parallel; placebo-controlled
Number of study sites: 57 local health units (860 general practitioners)
Dates: enrolment between February 2004 and March 2007, follow-up ended on 31
October 2011
Participants Inclusion criteria: clinical evidence of atherosclerotic CVD such as angina pectoris, PAD,
previous ischaemic stroke, TIA or revascularisation procedure; multiple risk factors (at
least 4 cardiovascular risk factors in nondiabetic patients and 1 or more in diabetics)
including: old age (≥ 65 years), men, history of arterial hypertension, history of hyperc-
holesterolaemia, smoking, obesity (BMI ≥ 30 kg/m2), family history of premature CVD
(< 55 years in father or brother; < 65 years in mother or sister); other conditions putting
the patient at high cardiovascular risk according to the general practitioner’s judgement
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Exclusion criteria: prior MI; allergy to n-3 PUFAs; pregnancy; diseases with predictable
poor short-term prognosis; and foreseeable psychological or logistic difficulties that
would affect compliance with the project
Sample size: 12,513 participants (total population), 1455 participants with history of
stroke and/or TIA
Participants randomised to intervention group (only stroke and/or TIA population): 736
Participants randomised to control group (only stroke and/or TIA population): 719
Sex (only stroke and/or TIA population): control = 420 men and 299 women, interven-
tion = 473 men and 263 women
Age, years + SD (only stroke and/or TIA population): control = 68.3 ± 9.2, intervention
= 68.4 ± 9.2
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: Italy
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo
Intervention: 1 g/day of marine-derived n-3 PUFAs ethyl esters with EPA and DHA
content not < 85%, in a ratio that could range from 0.9:1 to 1.5:1
Control: 1g/day of olive oil
Compliance: self-report
Duration of intervention: median of 5 years (IQR 4.0 to 5.5 years)
Co-interventions: N/A
Outcomes Primary outcome of study: composite of time to death from cardiovascular causes or
hospital admission for cardiovascular causes
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events; adverse events
Available outcome data for stroke and/or TIA population only: vascular-related death,
recurrent events; adverse events (combined)
Latest time point of assessment: median of 5 years (IQR 4.0 to 5.5 years)
Withdrawals or exclusions, n (stroke and/or TIA population only): control = 4, inter-
vention = 1
Study authors’ contact status: replied, data provided
Notes Dietary information: baseline fish consumption assessed. A post hoc analysis of the
efficacy of n-3 fatty acids in relation to baseline fish consumption (never or seldom, once
a week, twice a week, three times a week or more) showed no significant heterogeneity
(P = 0.46 for interaction)
Funding: Società Prodotti Antibiotici, Pfizer, and Sigma-Tau
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer-generated randomiza-
tion list stratified by GP”
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Allocation concealment (selection bias) Low risk Quote: “Treatment was centrally allocated
by telephone”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients, general practitioners, co-
ordination and statistical staff, and out-
come assessors were unaware of the study
assignments until the final analyses were
completed”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients, general practitioners, co-
ordination and statistical staff, and out-
come assessors were unaware of the study
assignments until the final analyses were
completed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk In total population (not only stroke sub-
sample), more participants discontinued
study treatment in the control group. How-
ever, reasons were specified and the only
1 significantly different among groups was
“patient’s decision”. Reasons related to ad-
verse reactions or clinical reasons did not
significantly differ between groups
Selective reporting (reporting bias) Low risk Protocol available. All pre-specified out-
comes were reported
Other bias Low risk None detected
Saito 2017
Methods RCT; parallel; open label
Number of study sites: 2
Dates: between March 2013 and October 2016
Participants Inclusion criteria: 18 to 69 years of age with a modified Fisher grade 3 or 4 SAH (short
axis of cisternal blood on CT ≥ 4 mm) who were admitted to the emergency department
during the first 72 hours after the initial bleeding episode; ruptured intracranial aneurysm
of the anterior circulation demonstrated by CTA or DSA; scheduled for surgical clipping
no earlier than 5 hours after CTA/DSA diagnosis; clinical condition at admission or
following medical stabilisation or external ventricular drainage placement was required
to be World Federation of Neurological Surgeons grades 1 to 4; stable “(hemodynamic:
70 <mean arterial pressure (MAP) <130 mm Hg; 90 <systolic blood pressure (SBP)
<180 mm Hg and headache <6 in the visual analogue scale [VAS]) at the intensive or
intermediate care unit (ICU or IMCU) before randomization”
Exclusion criteria: severe unstable acute or chronic systemic disturbances; antiplatelets,
anticoagulants or valproic acid during the 3 weeks before SAH; history of allergy to
iodine contrast media, fish or eggs; cerebral sequelae visible on admission CT; and refusal
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of informed consent
Sample size: 40 participants (all stroke population). Initially 41 participants were ran-
domised, however, 1 participant was excluded because baseline diagnosis was other than
stroke
Participants randomised to intervention group: 20 (initially 21, 1 participant excluded
as mentioned above)
Participants randomised to control group: 20
Sex: control = 7 men and 13 women, intervention = 8 men and 12 women
Age (years), median (range): control = 48 (20 to 67), intervention = 53 (22 to 68)
Time from event (stroke) to start of intervention: admission to the emergency department
within 72 hours after the initial bleeding episode
Type of baseline stroke: haemorrhagic
Country: Chile
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus open control
Intervention: 100 mL/day of the fish-oil-based lipid emulsion (FOLE), Omegaven 10%
(Fresenius Kabi Germany), administered intravenously for 5 consecutive days. The first
dose of FOLE had to be fully administered before beginning anaesthesia for aneurysm
surgery and was continued thereafter every 24 hours. Patients with a body weight less than
50 kg were required to receive an adjusted dose of 0.2 g FOLE/kg/day. Oral treatment:
Omacor 4 g/day (Ferrer Chile/Spain, Pronova BioPharma Norway) providing 1840 mg
of EPA and 1520 mg of DHA as ethyl esters, beginning the day after the last dose of
FOLE until 60th day after SAH. Patients in poor clinical condition and those with




Duration of intervention: 60 days
Co-interventions: medical stabilisation at an ICU/IMCU; 60 mg of oral nimodipine
every 4 hours
Outcomes Primary outcome of study: safety and feasibility of an effectiveness trial
Relevant review outcomes measured (in total population): efficacy (measured by Glasgow
Outcome Scale Extended score at 90 days); vascular-related death; incidence of other
type of stroke; adverse events
Available outcome data: efficacy (measured by Glasgow Outcome Scale Extended score
at 90 days); vascular-related death; incidence of other type of stroke; adverse events
Latest time point of assessment: 90 days
Withdrawals or exclusions, n: 1 participant (aetiology of initial haemorrhage other than
stroke)
Study authors’ contact status: replied, data provided
Notes Dietary information: the dietary provision of n-6 PUFAs (by regular diet or enteral
formula) did not exceed 9 g/day, and no additional n-3 PUFAs were given during the
hospital stay. Thus, the total n-6/n-3 PUFA supplementation ratio did not exceed 2.5/1.
Clinical dieticians supervised compliance with these instructions. Participants and their
relatives received written nutritional recommendations to be followed during outpatient
care: fish and seafood consumption had to be avoided during the treatment. Thereafter,
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participants were required to begin eating 2 portions of fatty fish twice weekly until the
third month after SAH. Foods with high n 6 PUFAs content (mayonnaise, margarine,
spreads and dressings, and vegetable oils except olive and canola) had to be avoided until
the third month after SAH
Funding: The Public Health Care Service of the VI Region (Servicio de Salud O’Higgins)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomized sequence was cre-
ated with permuted blocks whose sizes (4
and 6) were unknown until the end of the
trial. The randomization process was per-
formed by members of the medical society
of the VI Region who were not involved in
any other part of the trial or in the treat-
ment of neurosurgical patients”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized to treat-
ment groups using sequentially numbered
opaque sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Only the neuroradiologist was unaware of
group assignments (outcomes: incidence of
other type of stroke, and adverse events)
, other assessors were non-blinded (out-
come: efficacy)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data imputed adequately. Partici-
pants lost to follow-up distributed evenly
among groups
Selective reporting (reporting bias) Unclear risk Protocol not available for review (only
available in physical format at Regula-
tory Agency: Instituto de Salud Pública de
Chile)
Other bias Low risk None detected
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Methods RCT; parallel; placebo-controlled
Number of study sites: 1
Dates: recruitment between 1 September 1992 and 19 May 1994. 2 years of follow-up
Participants Inclusion criteria: stenosis greater than 20% in at least 1 vessel and revascularisation
(PTCA or coronary bypass surgery) planned or performed in the previous 6 months in
no more than 1 vessel
Exclusion criteria: history of cardiac transplantation; age younger than 18 years or older
than 75 years; haemodynamically relevant left main stenosis or proximal stenosis in all 3
main vessels; biplane left ventricular ejection fraction less than 35%; ventricular tachy-
cardias (≥ 3 QRS complexes); haemodynamically relevant cardiac valve disease; a prog-
nosis severely limited by noncardiac disease; bleeding tendency (e.g. due to thrombocy-
topenia or anticoagulation); diabetes, or other evidence of increased risk. Additionally:
participation in another study; psychiatric disease; history of noncompliance; living too
far away; initial coronary angiogram of poor quality; or history of allergic reaction to
contrast material
Sample size: 223 participants (total population), 6 participants with history of stroke
and/or TIA (with complete follow-up)
Participants randomised to intervention group (only stroke and/or TIA population): 3
(only participants with complete follow-up)
Participants randomised to control group (only stroke and/or TIA population): 3 (only
participants with complete follow-up)
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: ischaemic (including TIA)
Country: Germany
Ethnicity: not stated
Interventions Comparison groups: fish oil versus placebo
Intervention: during the first 3 months, 6 g/day of fish oil, providing 3.3 g/day of marine-
derived n-3 PUFAs (EPA plus DHA). For the following 21 months, 3 g/day of fish oil,
providing 1.65 g/day of marine-derived n-3 PUFAs (EPA plus DHA)
Control: fatty acids mixture without marine-derived n-3 PUFAs and reflecting the fatty
acid composition of the average European diet
Compliance: ’returned capsules’ count and analysis of red cell phospholipids fatty acids
Duration of intervention: 24 months
Co-interventions: N/A
Outcomes Primary outcome of study: changes on coronary angiography at 2 years, as assessed by
an expert panel
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events (stroke); adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 24 months
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: replied, no further data available
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SCIMO (Continued)
Notes Dietary information: overweight patients (body mass index > 25 kg/m²) were advised
to restrict caloric intake, and all patients were advised to avoid eating cholesterol-rich
foods; no other dietary advice was given
Funding: The Bundesministerium fur Forschung und Technologie, Germany, through
Gesellschaft fur Strahlenforschung (GSF, 07ERG03) and Deutsche Forschungsanstalt
fur Luft- und Raumfahrt (DLR, 01 EA 9501/7); Wilhelm Sander-Stiftung (93.032);
Fundacion Federico; and the Deutsche Forschungsgemeinschaft (Scha 398). Pronova,
A.S., Lysaker, Norway, provided the capsules and funds for monitoring
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A random sequence of study group
assignments was computer-generated by
the trial monitor in Norway”
Allocation concealment (selection bias) Low risk Quote: “The medication was prepared, en-
coded and sent from Norway”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All patients, study personnel in
contact with patients, and analytical per-
sonnel, were blinded with respect to study
medication”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All patients, study personnel in
contact with patients, and analytical per-
sonnel, were blinded with respect to study
medication”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants with complete follow-up bal-
anced across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
SU.FOL.OM3
Methods RCT; parallel; 2 × 2 factorial design
Number of study sites: 257
Dates: enrolment between 1 February 2003 and 1 June 2007. Last follow-up 1 July 2009
Participants Inclusion criteria: men and women aged 45 to 80 years; acute coronary or cerebral
ischaemic event within the 12 months before randomisation
Exclusion criteria: age (< 45 years or > 80 years); ill-defined diagnosis of cardiovascu-
lar disease; inability or unwillingness to comply with study treatment; and disease or
treatment that might interfere with metabolism of homocysteine or omega-3 fatty acids,
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in particular methotrexate for treating cancer or rheumatoid arthritis and chronic renal
failure (plasma creatinine concentration > 200 µmol/L or creatinine clearance < 40 ml/
min)
Sample size: 2501 participants (total population), 638 participants with history of stroke
Participants randomised to intervention group (only stroke population): 312 (148 to
marine-derived n-3 PUFAs only, and 164 to marine-derived n-3 PUFAs + B vitamins)
Participants randomised to control group (only stroke population): 326 (160 to placebo,
and 166 to B vitamins)
Sex (only stroke population): not stated
Age (only stroke population): not stated
Time from event (stroke) to start of intervention: median time between the acute CVD
event and randomisation was 101 days
Type of baseline stroke: ischaemic
Country: France
Ethnicity: not stated
Interventions Comparison groups: marine-derived n-3 PUFAs versus placebo. Participants were also
randomised to B vitamins or placebo, in a 2 × 2 factorial design
Intervention: 600 mg/day of EPA and DHA at a ratio of 2:1
Control: gelatin, fish-oil-flavoured capsules containing liquid paraffin
Compliance: self-reported (questionnaire or telephone interview)
Duration of intervention: median of 4.7 years (mean ± SD = 4.2 ± 1.0 years)
Co-interventions: participants also randomised to 5-methyltetrahydrofolate (560 µg),
vitamin B6 (3 mg) and B12 (20 µg) or placebo
Outcomes Primary outcome of study: first major cardiovascular event-non-fatal MI, ischaemic
stroke, or death from cardiovascular disease (including fatal MI, stroke, sudden death
(within 1 hour of onset of acute symptoms in the absence of violence or accident),
aortic dissection, cardiac failure, or other fatal event defined by the medical committee
as having a cardiovascular cause)
Relevant review outcomes measured (in total population): vascular-related death; recur-
rent events (ischaemic stroke); adverse events; and quality of life
Available outcome data for stroke population only: none
Latest time point of assessment: median of 4.7 years (mean ± SD = 4.2 ± 1.0 years)
Withdrawals or exclusions, n (stroke population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: none provided
Funding: French Ministry of Research (R02010JJ), Ministry of Health (DGS), Sodexo,
Candia, Unilever, Danone, Roche Laboratory, Merck EPROVA GS, and Pierre Fabre
Laboratory
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed by
means of a computerised block sequence
stratified by three age groups (44-54, 55-
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64, and 65-80 years), sex, prior disease
at enrolment (myocardial infarction, acute
coronary syndrome, or ischaemic stroke)
and recruitment centre. Permuted block
randomization (with block size randomly
selected as 8) was used”
Allocation concealment (selection bias) Low risk Quote: “The allocation of participants was
programmed by the statistical coordinating
centre. Once participants were random-
ized, the coordinating centre sent them suf-
ficient treatment capsules for one year (and
repeated yearly) in an appropriately labelled
package”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “Patients, clinicians, trial coordi-
nators, and outcome investigators were
blinded to treatment allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote “Patients, clinicians, trial coordi-
nators, and outcome investigators were
blinded to treatment allocation”
Quote: “All events were adjudicated by two
independent committees of cardiologists or
neurologists who were blinded to treatment
allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants that withdrew consent were
balanced across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk None detected
Terano 1999
Methods RCT; parallel; open label
Number of study sites: 1
Dates: not stated
Participants Inclusion criteria: men and women; living in a care home for the elderly; mild to moderate
dementia from cerebrovascular disorder
Exclusion criteria: not stated
Sample size: 20 participants
Participants randomised to intervention group (only stroke population): 10
Participants randomised to control group (only stroke population): 10
Sex (only stroke population): men and women (no details)
Age (only stroke population): average of 83 years (no further details)
Time from event (stroke) to start of intervention: not stated
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Type of baseline stroke: ischaemic (thrombotic)
Country: Japan
Ethnicity: not stated
Interventions Comparison groups: DHA versus no intervention (open control)
Intervention: 6 capsules containing 0.72 g/day of DHA
Control: no intervention
Compliance: nursing staff provided capsules and ascertained swallowing
Duration of intervention: 12 months
Co-interventions: N/A
Outcomes Primary outcome of study: effect of DHA on dementia
Relevant review outcomes measured (in total population): none
Available outcome data for stroke population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke population only): not stated
Study authors’ contact status: contact unsuccessfully attempted
Notes Dietary information: access to the same food (living in the same home)
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The controller randomly divided
the 20 elderly in two groups”
No description of the random sequence
generation
Allocation concealment (selection bias) Unclear risk No information on how the process of al-
location was conducted
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open label study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No loss of participants during follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Unclear risk Short communication; therefore
not enough information about study de-
sign, study outcomes (not relevant for this
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review) were not fully described. Addition-
ally, no information regarding Ethics Com-
mittee approval or funding of the trial
Thies 2003
Methods RCT; parallel; placebo-controlled. 3 arms: control oil, sunflower oil, and fish oil. For
this review the relevant arms are only control oil and fish oil
Number of study sites: 1
Dates: between May 1997 and December 1999
Participants Inclusion criteria: patients waiting to undergo carotid endarterectomy
Exclusion criteria: patients unwilling to participate in the study, patients who went to
surgery within 7 days from start of intervention
Sample size: 188 participants (total population), participants with history of stroke and/
or TIA
Participants randomised to intervention group (only stroke and/or TIA population): 46
(only participants who completed the trial, including symptoms within and more than
6 months before study entry, not clear if duplicates included)
Participants randomised to control group (only stroke and/or TIA population): 34 (only
participants who completed the trial, including symptoms within and more than 6
months before study entry, not clear if duplicates included)
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: UK
Ethnicity: not stated
Interventions Comparison groups: fish oil versus placebo (the study had 3 arms: control oil, sunflower
oil, and fish oil. For this review the relevant arms are only control oil and fish oil)
Intervention: fish oil 6 g/day
Control: blend of palm and soybean oils (80:20)
Compliance: ’returned capsules’ count and measurement of fatty-acid composition of
LDL lipid-fractions
Duration of intervention: median of 42 days (range, 7 to 189 days)
Co-interventions: N/A
Outcomes Primary outcome of study: plaque morphology indicative of stability or instability
Relevant review outcomes measured (in total population): adverse events
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: median of 42 days (range, 7 to 189 days)
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: replied, no data provided
Notes Dietary information: participants completed a 7-day weighed food diary and were advised
not to change their diet
Funding: a grant to RFG, PCC, and CPS from the Food Standards Agency (grant num-
ber ANO238). JMCG held a postgraduate studentship from the Ministry of Agricul-
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Thies 2003 (Continued)
ture, Fisheries, and Food. KR was supported by the Faculty of Medicine, Chiang Mai
University, Thailand, and the Royal Thai Government
Note: Dr Frank Thies was not involved in any stage of the analysis of this study for
the present review (screening, data extraction, and assessment of risk of bias). Contact
author is Prof PC Calder
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation of patients was
done according to a random number table,
by A Chulakadabba and KR. The sequence
was generated by computer”
Allocation concealment (selection bias) Low risk Quote: “Allocation was concealed in a
sealed envelope”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “We randomly allocated patients,
in a double-blind manner, to receive one
of three types of oil provided in capsules:
control oil, sunflower oil, or fish oil”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The only study outcome relevant for this
review is adverse events ascribed by partic-
ipants, who were blinded to intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Slightly more participants allocated to con-
trol group, more participants lost to follow-
up in fish oil group
Selective reporting (reporting bias) Unclear risk Protocol not available. Adverse events are
only reported as participant’s reason to
withdraw, not described if they were inter-
rogated for all participants
Other bias Low risk None detected
Wakita 2013
Methods RCT; parallel, open label
Number of study sites: not stated
Dates: not stated
Participants Inclusion criteria: patients with asymptomatic cerebral infarction and coronary artery
disease receiving 2 mg/day pitavastatin
Exclusion criteria: not stated
Sample size: 40 participants (all with history of stroke)
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Participants randomised to intervention group (only stroke and/or TIA population): 20
Participants randomised to control group (only stroke and/or TIA population): 20
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: ischaemic (cerebral infarction)
Country: not stated
Ethnicity: not stated
Interventions Comparison groups: EPA versus no EPA
Intervention: 1800 mg/day of EPA
Control: open control
Compliance: not stated
Duration of intervention: average of 8 months
Co-interventions: 2 mg/day of pitavastatin
Outcomes Primary outcome of study: efficacy of additional EPA to strong statin for carotid plaque
using carotid echography and pulse wave velocity
Relevant review outcomes measured (in total population): none
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: average of 8 months
Withdrawals or exclusions, n (stroke and/or TIA population only): not stated
Study authors’ contact status: no reply up to date
Notes Dietary information: none provided
Funding: not stated
Note: only abstract available (conference presentation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described
Allocation concealment (selection bias) Unclear risk No information about allocation process
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open label study (no additional informa-
tion given regarding outcome assessment)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up
Selective reporting (reporting bias) Unclear risk Protocol not available
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Other bias Unclear risk No full report available: therefore large
amount of information about study design
and conduct is missing
Zhang 2017
Methods RCT; parallel; placebo-controlled
Number of study sites: not stated (6 geographically convenient communities selected)
Dates: enrolment between March and April 2013. Follow-up 12 months
Participants Inclusion criteria: aged 65 years and over; in generally good health, ambulatory, and with
sufficient hearing and vision for compliance with testing procedures; absence of terminal
illness or mental disorders (i.e. major depression, schizophrenia, bipolar disorder, etc.);
not using any nutritional supplementation known to interfere with nutrition status, fatty
acid composition metabolism, or cognitive function in the 3 months before recruitment;
those able to undergo MRI evaluation (i.e. those without a pacemaker or other metal
items within the body, and those with MRI brain abnormalities such as multiple micro
haemorrhages, infarcts, or moderate to severe cortical atrophy); not living in a nursing
home or on a waiting list for a nursing home. From them, MCI was determined. People
with MCI who met the study criteria were selected
Exclusion criteria: exclusion criteria are not described in publications; however, they are
listed in the trial registration. Such exclusion criteria include history of stroke; nevertheless
participants with self-reported history of stroke/TIA were included in the trial
Exclusion criteria according to trial registration: neurological examination found the sign
of local central nerve obstruction such as obvious paralysis, unilateral sensory disturbance
and aphasia etc., history of cerebrovascular diseases (haemorrhagic and ischaemic stroke)
, brain injury or bone fracture; medical diseases such as asthmatic bronchitis, severe
hypertension, angina pectoris and severe infection; psychotic patients with evident anx-
iety and depressed emotion and people with endocrine system history of disease (hyper-
thyroidism, thyroid hypofunction, systemic lupus erythematosus, rheumatoid arthritis)
; newly discovered or advanced tumour; visual perception, auditory perceptual disor-
ders or language communication difficulties, all of which may influence measurement of
cognitive function; alcohol dependence and other psychoactive substance abuse such as
antipsychotic drug, benzodiazepines or taking medicine influencing cognitive function
Sample size: 240 participants (total population), 22 participants with history of stroke
and/or TIA
Participants randomised to intervention group (only stroke and/or TIA population): 12
Participants randomised to control group (only stroke and/or TIA population): 10
Sex (only stroke and/or TIA population): not stated
Age (only stroke and/or TIA population): not stated
Time from event (stroke or TIA) to start of intervention: not stated
Type of baseline stroke: not stated
Country: China
Ethnicity: Chinese
Interventions Comparison groups: DHA versus placebo
Intervention: 2 g/day of algal-derived DHA (Martek Biosciences) containing approxi-
mately 45% to 55% of DHA by weight
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Control: identical corn oil capsules (all capsules were orange-flavoured)
Compliance: capsule count and blood assessment at baseline, 6, and 12 months
Duration of intervention: 12 months
Co-interventions: N/A
Outcomes Primary outcome of study: cognitive function
Relevant review outcomes measured (in total population): none
Available outcome data for stroke and/or TIA population only: none
Latest time point of assessment: 12 months
Withdrawals or exclusions, n (stroke and/or TIA population only): not available
Study authors’ contact status: no reply to date
Notes Dietary information: at baseline, groups were similar for fish consumption. Dietary
recommendations based on a booklet (Guides to Enhance Elderly Memory) were provided
to all participants
Funding: Chinese Nutrition Society (CNS) Nutrition Research Foundation-DSM Re-
search Fund (grant number: 2014-003)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization sequence was
computer generated by the study sponsor”
Allocation concealment (selection bias) Low risk Quote: “The supplements were packaged
into identical pots, each containing 180
capsules, and labelled by staff who were not
involved in the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The supplements were packaged
into identical pots, each containing 180
capsules, and labelled by staff who were not
involved in the study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All project staff were unaware of
group assignments until the completion of
the trial and after data analysis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar amount of participants lost to fol-
low-up across groups
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk As stated above, trial registration includes
history of stroke as exclusion criteria; par-
ticipants with history of stroke are in-
cluded, however, and there is no mention
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of any exclusion criteria in the published
articles
AF: atrial fibrillation
ALA: alpha linolenic acid
AVF: arteriovenous fistula
BMI: body mass index
CABG: coronary artery bypass graft
CAS: carotid angioplasty and stenting
CT: computed tomography




DSA: digital subtraction angiography
EPA: eicosapentaenoic acid
FFQ: food frequency questionnaire
FOLE: fish oil-based lipid emulsion
HbA1c: glycated haemoglobin
ICU: intensive care unit
IQR: interquartile range
LMWH: low molecular weight heparin
LVEF: left ventricular ejection fraction
MCI: mild cognitive impairment
MI: myocardial infarction
MMSE: Mini Mental State Examination
MRI: magnetic resonance imaging
mRS: modified Rankin scale
N/A: not applicable
NYHA: New York Heart Association
PAD: peripheral artery disease
PCI: percutaneous coronary intervention
PTCA: percutaneous transluminal coronary angioplasty
PUFAs: polyunsaturated fatty acids
RCT: randomised controlled trial
SAH: subarachnoid haemorrhage
TIA: transient ischaemic attack
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
ALVINA 2013 Another active intervention in only 1 group (multiple lifestyle changes)
ANCHOR No stroke participants (baseline characteristics)
Bao 2016 Another active intervention in only 1 group (dietary supplement)
DOIT 1997 No stroke participants (baseline characteristics)
EVAS 2004 Quasi-randomised study (alternation)
FISHb Sandesara 2012 No stroke participants (baseline characteristics)
MARINE No stroke participants (baseline characteristics)
Nakagawa 2017 Not randomised study (participants of each group admitted in 2 different periods)
NCT01526824 No publications. Contact unsuccessfully attempted
SOFA Not clear if stroke participants were included (study authors confirmed that no further information is
available)
Suehiro 1994 Study design (randomisation) not indicated
Tomiyama 2005 Quasi-randomised study (month of birth odd/even)
Yoneda 2008 Quasi-randomised study (alternation)
Characteristics of studies awaiting assessment [ordered by study ID]
FISH Lok 2012
Methods RCT; parallel; placebo-controlled
Participants Individuals with end stage renal disease who require a synthetic graft for chronic haemodialysis
Interventions Intervention: fish oil
Control: corn oil
Outcomes Primary outcome of study: proportion of AV-grafts with loss of native patency
Notes Pending confirmation from study authors regarding inclusion of participants with stroke/TIA
Please note that there exists another study with the same acronym (FISH), see FISHb Sandesara 2012
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Hertantows 2014
Methods RCT; parallel; placebo-controlled
Participants Acute ischaemic stroke patients
Interventions Intervention: snakehead fish extract
Control: placebo (no details)
Outcomes Primary outcome of study: protein status, antioxidants and oxidative stress
Notes Pending confirmation from study authors regarding composition of intervention (i.e. proteins or fatty acids)
Nomura 2009
Methods RCT; parallel; 3 arms
Participants Patients with diabetes and hyperlipidaemia and normolipidemic controls
Interventions 3 arms: EPA, pitavastatin, or both interventions.
Outcomes Study primary outcome: effect on platelet-derived microparticles and adiponectin
Notes Pending confirmation from authors regarding distribution of stroke participants across intervention arms
ORIGIN
Methods RCT; parallel; 2 × 2 factorial design
Participants People with high risk for a cardiovascular event and impaired glucose tolerance or diabetes
Interventions Intervention: marine-derived n-3 PUFAs ethyl esters
Control: olive oil
Participants were randomised at the same time to either insulin glargine (Lantus, Sanofi Aventis) or standard ap-
proaches to glycaemic control
Outcomes Primary outcome of study: death from cardiovascular causes (for the marine-derived n-3 PUFAs arm)
Notes Pending confirmation from study authors regarding inclusion and number of stroke/TIA participants. Baseline
characteristics grouped “myocardial infarction, stroke, or revascularization”
REDUCE-IT
Methods RCT; parallel; placebo-controlled
Participants People with established cardiovascular disease (≥ 45 years) or age ≥ 50 years with diabetes mellitus in combination
with 1 additional risk factor for cardiovascular disease
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REDUCE-IT (Continued)
Interventions Intervention: icosapent ethyl (AMR101)
Control: mineral oil
Outcomes Primary outcome of study: a composite of cardiovascular death, nonfatal myocardial infarction (including silent
myocardial infarction), nonfatal stroke, coronary revascularisation, or unstable angina in a time-to-event analysis
Notes Pending confirmation from authors regarding inclusion of stroke/TIA participants, only described in baseline char-
acteristics as “secondary prevention cohort” from cardiovascular risk stratum
Sengoku 2013
Methods Parallel; open label
Participants Patients with cerebral infarction and dyslipidaemia
Interventions Intervention: EPA plus atorvastatin
Control: atorvastatin only
Outcomes Primary outcome of study: Cardio-Ankle Vascular Index
Notes Pending confirmation from study author regarding study design (randomisation) and details
EPA: eicosapentaenoic acid
MI: myocardial infarction
PUFAs: polyunsaturated fatty acids
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT01953705
Trial name or title n-3 PUFA for vascular cognitive aging
Methods RCT; parallel; placebo-controlled
Participants Older adults at high risk for cognitive decline and dementia of Alzheimer’s type
Interventions Intervention: marine-derived n-3 PUFAs
Control: soybean oil
Outcomes Primary outcome: total cerebral white matter hyperintensity volume
Starting date May 2014
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Contact information Lynne Shinto, ND, MPH
Oregon Health and Science University
shintol@ohsu.edu
Notes Study author confirmed that lacunar infarcts and TIAs are not exclusions if Clinical Dementia Rating ≤ 0.
50 and MMSE ≥ 24
Estimated study completion date: September 2019
OMEMI
Trial name or title Omega-3 fatty acids in elderly patients with acute myocardial infarction (OMEMI)
Methods RCT; parallel; placebo-controlled
Participants Elderly population with acute MI
Interventions Intervention: Pikasol® (EPA + DHA)
Control: corn oil
Outcomes Primary outcome: combined total mortality, first event of non-fatal MI, stroke and revascularisation
Starting date November 2012
Contact information Principal Investigator: Kristian Laake, MD
Oslo University Hospital
Notes Estimated study completion date: November 2019
STRENGTH
Trial name or title Outcomes study to assess statin residual risk reduction with EpaNova in high CV risk patients with hyper-
triglyceridemia (STRENGTH)
Methods RCT; parallel; placebo-controlled
Participants People with high risk for atherosclerotic cardiovascular disease
Interventions Intervention: Epanova®
Control: corn oil
Outcomes Time to the first occurrence of any component of the composite of major adverse cardiovascular events (car-
diovascular death, non-fatal MI, non-fatal stroke, emergent/elective coronary revascularisation, or hospitali-
sation for unstable angina)
Starting date 30 October 2014
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Contact information Stephen J Nicholls, MBBS, PhD,
South Australian Health and Medical Research Institute
stephen.nicholls@sahmri.com




PUFAs: polyunsaturated fatty acids
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy:
follow-up of 3 months or sooner




participants Statistical method Effect size
1 Efficacy (poor clinical outcome) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Vascular-related death 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Recurrent events (all: fatal and
non-fatal)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Incidence of other type of stroke 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Participants with prior
ischaemic stroke
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Participants with prior
haemorrhagic stroke
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events (all) 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Adverse events (extracranial
haemorrhage)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Adverse events (bleeding
complications)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Quality of life (mean change
from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 SF-36 questionnaire
Physical component scale
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 SF-36 questionnaire
Mental Component Scale
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Mood (GHQ-30, mean change
from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy:
follow-up longer than 3 months




participants Statistical method Effect size
1 Efficacy (Barthel Index) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Efficacy (Rivermead Mobility
Index)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Vascular-related death 5 2237 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.78, 1.35]
4 All recurrent events (fatal and
non-fatal)
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Recurrent events (fatal only) 3 1819 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.31, 1.55]
6 Recurrent events (non-fatal only) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7 Adverse events (all) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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8 Mood (GHQ-28) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 1 Efficacy (poor clinical outcome).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner




PUFAs Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saito 2017 7/20 9/20 0.78 [ 0.36, 1.68 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
Analysis 1.2. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 2 Vascular-related death.
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner












FOILS 0/51 1/51 0.33 [ 0.01, 8.00 ]
Saito 2017 0/20 1/20 0.33 [ 0.01, 7.72 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 1.3. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 3 Recurrent events (all: fatal and non-fatal).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner




PUFAs Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Foroughinia 2018 0/8 1/10 0.41 [ 0.02, 8.84 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 1.4. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 4 Incidence of other type of stroke.
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner




PUFAs Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Participants with prior ischaemic stroke
Foroughinia 2018 2/8 0/10 6.11 [ 0.33, 111.71 ]
2 Participants with prior haemorrhagic stroke
Saito 2017 5/20 8/20 0.63 [ 0.25, 1.58 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
Analysis 1.5. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 5 Adverse events (all).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner












Foroughinia 2018 1/8 5/10 0.25 [ 0.04, 1.73 ]
Saito 2017 0/20 1/19 0.32 [ 0.01, 7.35 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 1.6. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 6 Adverse events (extracranial haemorrhage).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner






n-3 PUFAs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Foroughinia 2018 1/8 5/10 0.25 [ 0.04, 1.73 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
Analysis 1.7. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 7 Adverse events (bleeding complications).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner






n-3 PUFAs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Saito 2017 0/20 1/19 0.32 [ 0.01, 7.35 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 1.8. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 8 Quality of life (mean change from baseline).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 SF-36 questionnaire Physical component scale
FOILS 51 0.07 (7.2843) 51 2.38 (5.4989) -2.31 [ -4.81, 0.19 ]
2 SF-36 questionnaire Mental Component Scale
FOILS 51 -0.68 (11.0692) 51 1.48 (7.9984) -2.16 [ -5.91, 1.59 ]
-50 -25 0 25 50
Favours [No n-3 PUFAs] Favours [N-3 PUFAs]
Analysis 1.9. Comparison 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up of 3 months or sooner, Outcome 9 Mood (GHQ-30, mean change from baseline).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 1 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up of 3 months or sooner









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
FOILS 51 -0.67 (3.0708) 51 -2.08 (3.785) 1.41 [ 0.07, 2.75 ]
-50 -25 0 25 50
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 2.1. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 1 Efficacy (Barthel Index).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
NUTRISTROKE 32 82.59 (21.41) 20 75.5 (22.25) 7.09 [ -5.16, 19.34 ]
-100 -50 0 50 100
Favours [No n-3 PUFAs] Favours [N-3 PUFAs]
Analysis 2.2. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 2 Efficacy (Rivermead Mobility Index).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
NUTRISTROKE 32 11.35 (4.79) 20 10.05 (4.59) 1.30 [ -1.31, 3.91 ]
-100 -50 0 50 100
Favours [No n-3 PUFAs] Favours [N-3 PUFAs]
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Analysis 2.3. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 3 Vascular-related death.
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months












ALPHA OMEGA 29/181 24/164 24.2 % 1.09 [ 0.67, 1.80 ]
GISSI HF 55/168 49/178 45.1 % 1.19 [ 0.86, 1.64 ]
NUTRISTROKE 0/38 4/34 0.9 % 0.10 [ 0.01, 1.79 ]
OPAL 0/10 1/9 0.8 % 0.30 [ 0.01, 6.62 ]
Risk % Prevention Study 35/736 40/719 29.1 % 0.85 [ 0.55, 1.33 ]
Total (95% CI) 1133 1104 100.0 % 1.02 [ 0.78, 1.35 ]
Total events: 119 (Marine-derived N-3 PUFAs), 118 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.74, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
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Analysis 2.4. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 4 All recurrent events (fatal and non-fatal).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months












GISSI HF 16/168 7/178 2.42 [ 1.02, 5.74 ]
JELIS 33/485 48/457 0.65 [ 0.42, 0.99 ]
Risk % Prevention Study 24/736 22/719 1.07 [ 0.60, 1.88 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
Analysis 2.5. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 5 Recurrent events (fatal only).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months














ALPHA OMEGA 6/181 5/164 47.7 % 1.09 [ 0.34, 3.50 ]
OPAL 0/10 1/9 6.8 % 0.30 [ 0.01, 6.62 ]
Risk % Prevention Study 4/736 8/719 45.5 % 0.49 [ 0.15, 1.61 ]
Total (95% CI) 927 892 100.0 % 0.69 [ 0.31, 1.55 ]
Total events: 10 (Marine-derived n-3 PUFAs), 14 (No marine n-3 PUFAs)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
102Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 6 Recurrent events (non-fatal only).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months






n-3 PUFAs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Risk % Prevention Study 14/736 20/719 0.68 [ 0.35, 1.34 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
Analysis 2.7. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 7 Adverse events (all).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months




PUFAs Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Risk % Prevention Study 27/736 28/719 0.94 [ 0.56, 1.58 ]
0.01 0.1 1 10 100
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
103Marine-derived n-3 fatty acids therapy for stroke (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.8. Comparison 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty
acids therapy: follow-up longer than 3 months, Outcome 8 Mood (GHQ-28).
Review: Marine-derived n-3 fatty acids therapy for stroke
Comparison: 2 Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy: follow-up longer than 3 months









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
OPAL 9 2.33 (4.03) 5 1.33 (1.8) 1.00 [ -2.07, 4.07 ]
-50 -25 0 25 50
Favours [N-3 PUFAs] Favours [No n-3 PUFAs]
A D D I T I O N A L T A B L E S
Table 1. Sample characteristics in included studies providing outcome data
Study ID Stroke/TIA popu-
lation, n





Studies with follow-up of three months or less




= 64 ± 10
Control group = 65
± 12
Ischaemic Median (IQR)
Fish oil group = 1.
18 (0.5, 2.1) years
Placebo oil group =
0.90 (0.5, 2.3) years
Foroughinia 2018 18 9 men
9 women




= 75.2 ± 6.2 (Range:
Ischaemic Not stated
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Table 1. Sample characteristics in included studies providing outcome data (Continued)
65 to 82)
Control group = 71.
7 ± 6.8 (Range: 57
to 83)













hours after the ini-
tial bleeding episode
Studies with follow-up of more than three months
ALPHA OMEGA 345 264 men
81 women
Mean + SD, Me-
dian, Range
EPA-DHA = 70.95
± 5.68, 71.49, 60.1
to 80.9
EPA-DHA + ALA =
69.92 ± 5.89, 70.36,
60.2 to 80.0
ALA = 70.34 ± 5.39,
71.52, 60.4 to 80.2
Placebo = 70.38 ± 5.
58, 71.04, 59.8 to
80.6
Overall (n = 345):
Mean 70.4 ± 5.6,
71.0, range 60.0 to
80.9
Not stated Not stated




= 71 ± 8
Control group = 70
± 9
Not stated Not stated




= 66 ± 7





(6 months or more,
as per exclusion cri-
teria)
NUTRISTROKE 72 47 men
25 women
Mean (± SD proba-
bly, not specified)
Marine-derived n-3
PUFAs = 61.3 ± 13.
6
Marine-derived n-3
Ischaemic Less than 60 days (as
per exclusion crite-
ria)
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Table 1. Sample characteristics in included studies providing outcome data (Continued)
PUFAs + Antioxi-
dants = 66.3 ± 11.4
Antioxidants = 65.1
± 12.8
Placebo = 68.4 ± 12.
6




= 75.16 ± 2.65
Control group = 75.
04 ± 3.17








Control = 68.3 ± 9.
2
Not stated Not stated




PUFAs: polyunsaturated fatty acids
SD: standard deviation
TIA: transient ischaemic attack
Table 2. Characteristics of the interventions in included studies providing data
Study ID Type of inter-
vention
Dose Control Length of inter-
vention
Lat-




Studies with follow-up of three months or less









of palm and soy
oils)
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Table 2. Characteristics of the interventions in included studies providing data (Continued)
600 mg, then 75
mg/day)
- Aspirin (load-
ing dose of 325
mg, then 80 mg/
day)


















less than 50 kg)
Omacor =
1840 mg of EPA






60 days (5 in-
travenous treat-
ment and 55 oral
treatment)
90 days - Medical stabili-
sation
- 60 mg of oral
nimodipine ev-
ery 4 hours

















ALA (2 g/day) or
Placebo









3.9 (3.0 to 4.5)
years
Median (IQR)

























Fish oil capsules 250 mg of DHA
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Table 2. Characteristics of the interventions in included studies providing data (Continued)
mg vitamin C,
150 mg polyphe-
nols and 19 mg
β-carotene) or
placebo
OPAL Ethyl esters cap-
sules
200 mg of EPA










At least 850 mg







5 (4.0 to 5.5)
years
Median (IQR)
5 (4.0 to 5.5)
years
N/A
ALA: alpha linolenic acid





PUFAs: polyunsaturated fatty acids
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1MeSH descriptor: [Cerebrovascular Disorders] this term only
#2MeSH descriptor: [Basal Ganglia Cerebrovascular Disease] this term only
#3MeSH descriptor: [Brain Ischemia] explode all trees
#4MeSH descriptor: [Carotid Artery Diseases] explode all trees
#5MeSH descriptor: [Cerebral Small Vessel Diseases] explode all trees
#6MeSH descriptor: [Intracranial Arterial Diseases] explode all trees
#7MeSH descriptor: [Intracranial Embolism and Thrombosis] explode all trees
#8MeSH descriptor: [Intracranial Hemorrhages] explode all trees
#9MeSH descriptor: [Stroke] this term only
#10MeSH descriptor: [Brain Infarction] explode all trees
#11MeSH descriptor: [Stroke, Lacunar] this term only
#12MeSH descriptor: [Vasospasm, Intracranial] this term only
#13MeSH descriptor: [Vertebral Artery Dissection] this term only
#14(stroke* or poststroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva* or SAH):ti,ab,kw (Word variations have
been searched)
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#15(((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
near/5 (ischaemi* or ischemi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*))):ti,ab,kw (Word variations have been searched)
#16(((brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid) near/5 (haemorrhag* or
haemorrhag* or haematoma* or hematoma* or bleed*))):ti,ab,kw (Word variations have been searched)
#17MeSH descriptor: [Hemiplegia] this term only
#18MeSH descriptor: [Paresis] explode all trees
#19MeSH descriptor: [Gait Disorders, Neurologic] explode all trees
#20(hemipleg* or hemipar* or paresis or paraparesis or paretic):ti,ab,kw (Word variations have been searched)
#21MeSH descriptor: [Gait Disorders, Neurologic] explode all trees
#22(hemipleg* or hemipar* or paresis or paraparesis or paretic):ti,ab,kw (Word variations have been searched)
#23{or #1-#22}
#24MeSH descriptor: [Fish Oils] explode all trees
#25MeSH descriptor: [Fatty Acids] this term only
#26MeSH descriptor: [Fatty Acids, Omega-3] this term only
#27MeSH descriptor: [Docosahexaenoic Acids] this term only
#28MeSH descriptor: [Eicosapentaenoic Acid] this term only
#29MeSH descriptor: [Fishes] explode all trees
#30MeSH descriptor: [Seafood] this term only
#31MeSH descriptor: [Fish Products] this term only
#32MeSH descriptor: [Shellfish] this term only
#33MeSH descriptor: [Dietary Fats] this term only
#34(((fish* or cod or mackerel or kipper* or pilchards or tuna or trout or sprat* or salmon or herring or crab or whitebait or swordfish or
sardine* or krill or microalgae or marine) near/3 (oil* or fat* or acid* or “omega-3” or omega3 or “omega 3” or “n-3” or polyunsaturat*))
or PUFA*):ti,ab,kw (Word variations have been searched)
#35((Docosahexaenoic or eicosapentaenoic or icosapentaenoic) near/3 acid*):ti,ab,kw (Word variations have been searched)
#36(EPA or DHA):ti,ab,kw (Word variations have been searched)
#37{or #24-#36}
#38#23 and #37
Appendix 2. MEDLINE (Ovid) search strategy
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
cerebral small vessel diseases/ or exp intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial
hemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/ or exp Gait Disorders, Neurologic/
6. (hemipleg$ or hemipar$ or paresis or paraparesis or paretic).tw.
7. or/1-6
8. exp fish oils/ or fatty acids/ or fatty acids, omega-3/ or docosahexaenoic acids/ or eicosapentaenoic acid/
9. exp Fishes/ or seafood/ or fish products/ or shellfish/ or Dietary Fats/
10. (((fish$ or cod or mackerel or kipper$ or pilchards or tuna or trout or sprat$ or salmon or herring or crab or whitebait or swordfish
or sardine$ or krill or microalgae or marine) adj3 (oil$ or fat$ or acid$ or omega-3 or omega3 or omega 3 or n-3 or polyunsaturat$))
or PUFA$).tw.
11. ((Docosahexaenoic or eicosapentaenoic or icosapentaenoic) adj3 acid$).tw.
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12. (EPA or DHA).tw.
13. or/8-12
14. Randomized Controlled Trials as Topic/
15. Random Allocation/
16. Controlled Clinical Trials as Topic/
17. control groups/
18. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or






24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
27. (random$ or RCT or RCTs).tw.
28. (controlled adj5 (trial$ or stud$)).tw.
29. (clinical$ adj5 trial$).tw.
30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
32. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
33. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
34. (cross-over or cross over or crossover).tw.
35. (placebo$ or sham).tw.
36. trial.ti.
37. (assign$ or allocat$).tw.
38. controls.tw.
39. or/14-38
40. 7 and 13 and 39
Appendix 3. Embase (Ovid) search strategy
1. cerebrovascular disease/ or brain disease/ or exp basal ganglion hemorrhage/ or exp brain hemangioma/ or exp brain hematoma/
or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp carotid artery disease/ or exp cerebral artery disease/
or exp cerebrovascular accident/ or exp cerebrovascular malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular
disease/ or exp vertebrobasilar insufficiency/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. exp hemiplegia/ or exp paresis/
6. or neurologic gait disorder/
7. (hemipleg$ or hemipar$ or paresis or paraparesis or paretic).tw.
8. or/1-7
9. exp fish oil/ or omega 3 fatty acid/ or long chain fatty acid/ or very long chain fatty acid/ or unsaturated fatty acid/ or polyunsaturated
fatty acid/ or icosapentaenoic acid/ or icosapentaenoic acid ethyl ester/ or docosahexaenoic acid/
10. exp fish/ or fish meat/ or fish meal/ or fish product/ or sea food/ or shellfish/ or alga/ or cod liver oil/ or edible oil/ or fat intake/
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11. (((fish$ or cod or mackerel or kipper$ or pilchards or tuna or trout or sprat$ or salmon or herring or crab or whitebait or swordfish
or sardine$ or krill or microalgae or marine) adj3 (oil$ or fat$ or acid$ or omega-3 or omega3 or omega 3 or n-3 or polyunsaturat$))
or PUFA$).tw.
12. ((Docosahexaenoic or eicosapentaenoic or icosapentaenoic) adj3 acid$).tw.
13. (EPA or DHA).tw.
14. 9 or 10 or 11 or 12 or 13
15. Randomized Controlled Trial/ or “randomized controlled trial (topic)”/
16. Randomization/
17. Controlled clinical trial/ or “controlled clinical trial (topic)”/
18. control group/ or controlled study/
19. clinical trial/ or “clinical trial (topic)”/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical
trial/
20. Crossover Procedure/
21. Double Blind Procedure/
22. Single Blind Procedure/ or triple blind procedure/
23. placebo/ or placebo effect/
24. (random$ or RCT or RCTs).tw.
25. (controlled adj5 (trial$ or stud$)).tw.
26. (clinical$ adj5 trial$).tw.
27. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
28. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
29. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
30. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
31. (cross-over or cross over or crossover).tw.
32. (placebo$ or sham).tw.
33. trial.ti.
34. (assign$ or allocat$).tw.
35. controls.tw.
36. or/15-35
37. 8 and 14 and 36
Appendix 4. CINAHL EBSCO search strategy
S1(MH “Cerebrovascular Disorders”) OR (MH “Basal Ganglia Cerebrovascular Disease+”) OR (MH “Carotid Artery Diseases+”) OR
(MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR ( (MH “Intracranial
Embolism and Thrombosis”) ) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral Artery Dissections”)
OR (MH “Stroke Patients”) OR (MH “Stroke Units”)
S2TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH ) or AB ( stroke or
poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH)
S3TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or intracerebral)
S4TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or thrombo* or
emboli* or occlus*)
S5S3 AND S4
S6TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid ) or AB ( brain* or cerebr* or cerebell* or intracerebral
or intracranial or subarachnoid)
S7TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed*)
S8S6 AND S7
S9TI transient ischaemic attack* or TI transient ischemic attack* or AB transient ischaemic attack* or AB transient ischemic attack*
or TI TIA or TI TIA s or AB TIA or AB TIAs
S10(MH “Hemiplegia”)
S11TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic )
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S12S1 OR S2 OR S5 OR S8 OR S9 OR S10 OR S11
S13(MH “Fish Oils+”) OR (MH “Fatty Acids”) OR (MH “Fatty Acids, Omega-3”) OR (MH “Docosahexaenoic Acids”) OR (MH
“Eicosapentaenoic Acid”)
S14(MH “Fish+”) OR (MH “Seafood”) OR (MH “Shellfish”) OR (MH “Crustacea”) OR (MH “Fats, Unsaturated”) OR (MH “Dietary
Fats”)
S15TX (((fish* OR cod OR mackerel OR kipper* OR pilchards OR tuna OR trout OR sprat* OR salmon OR herring OR crab OR
whitebait OR swordfish OR sardine* OR krill OR microalgae OR marine) N3 (oil* OR fat* OR acid* OR omega-3 OR omega3 OR
omega 3 OR n-3 OR polyunsaturat*)) OR PUFA*)
S16TX ((Docosahexaenoic OR eicosapentaenoic OR icosapentaenoic) N3 acid*)
S17TX (EPA OR DHA)
S18S13 OR S14 OR S15 OR S16 OR S17
S19(MH “Randomized Controlled Trials”) or (MH “Random Assignment”) or (MH “Random Sample+”)
S20(MH “Clinical Trials”) or (MH “Intervention Trials”) or (MH “Therapeutic Trials”)
S21(MH “Double-Blind Studies”) or (MH “Single-Blind Studies”) or (MH “Triple-Blind Studies”)
S22(MH “Control (Research)”) or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”)
S23(MH “Crossover Design”) OR (MH “Quasi-Experimental Studies”)
S24PT (clinical trial or randomized controlled trial)
S25TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
S26TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
S27TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
S28TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB ((control or treatment or
experiment* or intervention) N5 (group* or subject* or patient*))
S29((control or experiment* or conservative) N5 (treatment or therapy or procedure or manage*)) or AB ((control or experiment* or
conservative) N5 (treatment or therapy or procedure or manage*))
S30TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*))
S31TI (cross-over or cross over or crossover) or AB (cross-over or cross over or crossover)
S32TI (placebo* or sham) or AB (placebo* or sham)
S33TI trial
S34TI (assign* or allocat*) or AB (assign* or allocat*)
S35TI controls or AB controls
S36TI (quasi-random* or quasi random* or pseudo-random* or pseudo random*) or AB (quasi-random* or quasi random* or pseudo-
random* or pseudo random*)
S37S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33
OR S34 OR S35 OR S36
S38S12 AND S18 AND S37
Appendix 5. Web of Science search strategy
#1. TS=(stroke or poststroke or post-stroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva or SAH)
#2. TS=((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial
or “middle cerebral artery” or MCA* or “anterior circulation” or “posterior circulation” or “basilar artery” or “vertebral artery” or “space-
occupying”) NEAR/5 (isch$emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*))
#3. TS=((brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or
infratentorial or supratentorial or “basal gangli*” or putaminal or putamen or “posterior fossa” or hemispher* or subarachnoid) NEAR/
5 (h$emorrhage* or h$ematoma* or bleed*))
#4. TS=(hemipleg* or hemipar* or paresis or paraparesis or paretic)
#5. #1 OR #2 OR #3 OR #4
#6. TS=(((fish* or cod or mackerel or kipper* or pilchards or tuna or trout or sprat* or salmon or herring or crab or whitebait or
swordfish or sardine* or krill or microalgae or marine) NEAR/3 (oil* or fat* or acid* or omega-3 or omega3 or “omega 3” or n-3 or
polyunsaturat*)) or PUFA*)
#7. TS=((Docosahexaenoic or eicosapentaenoic or icosapentaenoic) NEAR/3 acid*)
#8. TS=(EPA or DHA)
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#9. #6 OR #7 OR #8
#10. TS=(random* or RCT or RCTs)
#11. TS=(controlled NEAR/5 (trial$ or stud*))
#12. TS=(clinical* NEAR/5 trial*)
#13. TS=((control or treatment or experiment* or intervention) NEAR/5 (group$ or subject$ or patient$))
#14. TS=(quasi-random* or quasi random* or pseudo-random* or pseudo random*)
#15. TS=((control$ or experiment* or conservative) NEAR/5 (treatment or therapy or manage* or procedure))
#16. TS=((doubl* or singl* or tripl* or trebl*) NEAR/5 (blind* or mask*))
#17. TS=(cross-over or cross over or crossover)
#18. TS=(placebo* or sham)
#19. TI=trial
#20. TS=(assign* or allocat*)
#21. TS=controls
#22. #10 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#24. #5 AND #9 AND #22
Appendix 6. US National Institutes of Health Ongoing Trial Register ClinicalTrials.gov search
strategy
( fish OR fatty acid OR dietary fat OR Omega 3 OR docosahexaenoic OR eicosapentaenoic OR sea OR marine )
AND
( Brain Infarction OR Intracranial Hemorrhages OR Carotid Artery Diseases OR Brain Ischemia OR Cerebral Hemorrhage OR
Cerebrovascular Disorders OR Stroke ) [DISEASE]




We adapted the search strategy for each registry
Appendix 8. ISRCTN Registry search strategy
Text search: (fish OR “fish oil” OR “fatty acids” OR “omega 3”) AND stroke
Appendix 9. World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP) search strategy
stroke AND fatty acids OR stroke AND dietary fats OR stroke AND marine OR stroke AND fish OR stroke AND sea
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Mary Joan Macleod: none known.
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at any stage (screening, data extraction and risk of bias assessment) and this study is not contributing any outcome data to the review.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
In order to improve clarity, we rephrased the secondary outcome “Incidence of different type of stroke (ischaemic or haemorrhagic)”
to “Incidence of other type of stroke (ischaemic or haemorrhagic)”. However, the criteria for assessing this outcome were not modified.
It refers to incidence, during follow-up, of a stroke different in type from the index event (i.e. if the index stroke was ischaemic, then
incidence of haemorrhagic stroke or vice versa).
Additionally, to enhance the reporting of all efficacy outcome measures included, we amended the methodology for the primary outcome
from: “For studies using multiple scales, we will select the one with the largest amount of data available or, in the case of equal amounts
of data, the one reported first in the study” to the following:
“For studies using multiple scales, we included all functional outcome and disability/dependency measures reported. However, for a
meta-analysis we would have selected the one with the largest amount of data available or, in the case of equal amounts of data, the one
reported first in the study”.
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